Cynosure (CYNO) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 10, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'CYNOSURE INC	'	'
Entity Central Index Key	'0000885306	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	22,263,116	'
Entity Public Float	'	'	$524,608,684

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$93,655	$86,057
Short-term marketable securities	26,633	40,617
Accounts receivable, net of allowance of $1,803 and $2,043 in 2013 and 2012, respectively	36,587	17,970
Inventories	54,098	32,906
Prepaid expenses and other current assets	6,891	5,149
Deferred income taxes	9,341	783
Total current assets	227,205	183,482
Property and equipment, net	26,445	8,207
Long-term marketable securities	8,804	20,071
Goodwill	95,183	15,811
Intangibles, net	55,179	5,937
Other assets	1,678	1,061
Total assets	414,494	234,569
Current liabilities:	'	'
Accounts payable	13,916	8,346
Amounts due to related party	1,268	1,896
Accrued expenses	36,977	17,201
Deferred revenue	9,163	6,319
Capital lease obligations	286	322
Total current liabilities	61,610	34,084
Capital lease obligations, net of current portion	14,957	432
Deferred revenue, net of current portion	1,010	281
Other noncurrent liabilities	8,565	2,265
Commitments and Contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value Authorized-5,000 shares as of December 31, 2013 and 2012 Issued-no shares as of December 31, 2013 and 2012	'	'
Class A and Class B common stock, $0.001 par value Authorized-70,000 shares as of December 31, 2013 and 2012 Issued-22,633 Class A shares and no Class B shares at December 31, 2013 Issued-16,402 Class A shares and no Class B shares at December 31, 2012	23	17
Additional paid-in capital	338,742	190,979
Retained earnings	8,636	10,283
Accumulated other comprehensive loss	-1,499	-1,599
Treasury stock, 886 Class A shares, at cost, at December 31, 2013; 233 Class A shares, at cost, at December 31, 2012	-17,550	-2,173
Total stockholders' equity	328,352	197,507
Total liabilities and stockholders' equity	$414,494	$234,569

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful account receivable	$1,803	$2,043
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Class A and Class B common stock, shares authorized	70,000,000	70,000,000
Common stock, par value	$0.00	'
Common Stock Class A [Member]	'	'
Class A and Class B common stock, shares authorized	61,500,000	'
Common stock, par value	$0.00	$0.00
Common stock, shares issued	22,632,749	16,402,000
Treasury stock, shares	886,000	233,000
Common Stock Class B [Member]	'	'
Class A and Class B common stock, shares authorized	8,500,000	'
Common stock, par value	$0.00	$0.00
Common stock, shares issued	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
Product revenues	$188,271	$128,513	$88,361
Parts, accessories, service and royalty revenues	37,739	24,980	22,241
Total revenues	226,010	153,493	110,602
Cost of revenues	95,730	64,567	48,294
Gross profit	130,280	88,926	62,308
Operating expenses:	'	'	'
Sales and marketing	64,347	47,543	39,142
Research and development	17,473	12,972	10,079
Amortization of intangible assets acquired	2,114	1,368	854
General and administrative	52,173	14,910	14,255
Total operating expenses	136,107	76,793	64,330
(Loss) income from operations	-5,827	12,133	-2,022
Interest (expense) income, net	-23	60	126
Other income (expense), net	313	532	-202
(Loss) income before (benefit) provision for income taxes	-5,537	12,725	-2,098
(Benefit) provision for income taxes	-3,890	1,764	807
Net (loss) income	($1,647)	$10,961	($2,905)
Basic net (loss) income per share	($0.09)	$0.83	($0.23)
Diluted net (loss) income per share	($0.09)	$0.79	($0.23)
Basic weighted average common shares outstanding	19,325	13,189	12,585
Diluted weighted average common shares outstanding	19,325	13,792	12,585

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement Of Income And Comprehensive Income [Abstract]	'	'	'
Net (loss) income	($1,647)	$10,961	($2,905)
Other comprehensive income (loss) components:	'	'	'
Cumulative translation adjustment	77	452	-97
Unrealized gain (loss) on marketable securities, net of taxes	23	-10	-6
Total other comprehensive income (loss)	100	442	-103
Comprehensive (loss) income	($1,547)	$11,403	($3,008)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Class A and B Common Stock [Member]	Class A and B Common Stock [Member]
In Thousands, except Share data						Treasury Stock [Member]
Beginning Balance at Dec. 31, 2010	$120,300	$121,706	$2,227	($1,938)	$13	($1,708)
Beginning Balance, shares at Dec. 31, 2010	'	'	'	'	12,761,000	-185,000
Stock-based compensation expense	2,559	2,559	'	'	'	'
Exercise of stock options	241	241	'	'	'	'
Exercise of stock options, shares	'	'	'	'	42,000	'
Repurchase of common stock	-465	'	'	'	'	-465
Repurchase of common stock, shares	'	'	'	'	'	-48,000
Net income (loss)	-2,905	'	-2,905	'	'	'
Cumulative translation adjustment	-97	'	'	-97	'	'
Unrealized gain (loss) on marketable securities, net of taxes	-6	'	'	-6	'	'
Ending Balance at Dec. 31, 2011	119,627	124,506	-678	-2,041	13	-2,173
Ending Balance, shares at Dec. 31, 2011	'	'	'	'	12,803,000	-233,000
Stock-based compensation expense	2,913	2,913	'	'	'	'
Exercise of stock options	7,158	7,157	'	'	1	'
Exercise of stock options, shares	'	'	'	'	759,000	'
Tax benefit from stock-based compensation expense in excess of book deductions	1,153	1,153	'	'	'	'
Public offering of common stock	55,253	55,250	'	'	3	'
Public offering of common stock, shares	'	'	'	'	2,840,000	'
Net income (loss)	10,961	'	10,961	'	'	'
Cumulative translation adjustment	452	'	'	452	'	'
Unrealized gain (loss) on marketable securities, net of taxes	-10	'	'	-10	'	'
Ending Balance at Dec. 31, 2012	197,507	190,979	10,283	-1,599	17	-2,173
Ending Balance, shares at Dec. 31, 2012	'	'	'	'	16,402,000	-233,000
Stock-based compensation expense	3,694	3,694	'	'	'	'
Exercise of stock options	2,721	2,721	'	'	'	'
Exercise of stock options, shares	202,603	'	'	'	203,000	'
Tax benefit from stock-based compensation expense in excess of book deductions	563	563	'	'	'	'
Repurchase of common stock	-15,377	'	'	'	'	-15,377
Repurchase of common stock, shares	'	'	'	'	'	-653,000
Issuance of common stock associated with acquisition of Palomar	141,359	141,353	'	'	6	'
Issuance of common stock associated with acquisition of Palomar, shares	'	'	'	'	6,028,000	'
Equity issuance costs associated with acquisition of Palomar	-568	-568	'	'	'	'
Net income (loss)	-1,647	'	-1,647	'	'	'
Cumulative translation adjustment	77	'	'	77	'	'
Unrealized gain (loss) on marketable securities, net of taxes	23	'	'	23	'	'
Ending Balance at Dec. 31, 2013	$328,352	$338,742	$8,636	($1,499)	$23	($17,550)
Ending Balance, shares at Dec. 31, 2013	'	'	'	'	22,633,000	-886,000

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	Dec. 31, 2013
Statement Of Stockholders Equity [Abstract]	'
Class A and B Common Stock	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities:	'	'	'
Net (loss) income	($1,647)	$10,961	($2,905)
Reconciliation of net (loss) income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	9,103	6,870	6,894
Impairment loss on assets held for sale	607	'	'
Stock-based compensation	3,688	2,910	2,561
Loss (gain) on disposal of fixed assets	100	-19	-55
Deferred income taxes	-5,284	-352	-46
Net accretion of marketable securities	1,448	1,480	1,086
Changes in operating assets and liabilities, excluding effect of business combination:	'	'	'
Accounts receivable	-9,132	-4,861	-469
Inventories	-5,591	-6,183	-10,343
Net book value of demonstration inventory sold	604	884	999
Prepaid expenses and other current assets	540	-980	908
Accounts payable	-1,724	-151	2,168
Due to related party	-628	347	-238
Tax benefit from stock option exercises	-565	-1,178	-33
Accrued expenses	11,145	4,704	3,254
Deferred revenue	816	-135	2,395
Other noncurrent liabilities	-102	319	2
Net cash provided by operating activities	3,378	14,616	6,178
Investing activities:	'	'	'
Purchases of property and equipment	-3,457	-3,116	-903
Proceeds from the sale of property and equipment	25,206	'	'
Proceeds from the sales and maturities of securities	84,054	45,400	84,820
Purchases of marketable securities	-23,088	-69,878	-54,488
Cash paid for acquisitions, net of cash received	-64,978	'	-26,970
(Increase) decrease in other assets	-519	110	-34
Net cash provided by (used in) investing activities	17,218	-27,484	2,425
Financing activities:	'	'	'
Excess tax benefit on options exercised	565	1,178	33
Repurchases of common stock	-15,377	'	-465
Proceeds from public offering of common stock	'	55,253	'
Proceeds from stock option exercises	2,721	7,158	241
Acquisition-related equity issuance costs	-568	'	'
Payments on capital lease obligation	-320	-305	-102
Net cash (used in) provided by financing activities	-12,979	63,284	-293
Effect of exchange rate changes on cash and cash equivalents	-19	-53	-50
Net increase in cash and cash equivalents	7,598	50,363	8,260
Cash and cash equivalents, beginning of year	86,057	35,694	27,434
Cash and cash equivalents, end of year	93,655	86,057	35,694
Supplemental cash flow information:	'	'	'
Cash paid for interest	25	42	32
Cash paid for income taxes	1,030	1,767	1,160
Supplemental noncash investing and financing activities:	'	'	'
Transfer of demonstration equipment from inventory to fixed assets	6,190	2,988	3,205
Assets acquired under capital lease	14,828	351	695
Fair value of shares issued in acquisition	$141,359	'	'

Nature_of_the_Business

Nature of the Business	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Nature of the Business	'
	1. Nature of the Business
	Cynosure, Inc. (“Cynosure” or “the Company”) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Cynosure markets and sells its products primarily to the dermatology, plastic surgery and general medical markets, both domestically and internationally. Cynosure is a Delaware corporation, incorporated on July 10, 1991, located in Westford, Massachusetts.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Significant accounting policies followed in the preparation of these consolidated financial statements are as follows:
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures at the date of the financial statements and during the reporting period. Components particularly subject to estimation include the allowance for doubtful accounts, inventory reserves, intangible assets, impairment analysis of goodwill and intangibles, deferred tax assets, liabilities and valuation allowances, fair value of stock options and investments and accrued warranties. On an ongoing basis, management evaluates its estimates. Actual results could differ from these estimates.
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Cynosure, Inc. and its wholly owned subsidiaries: Cynosure GmbH, Cynosure S.A.R.L., Cynosure UK Limited, Cynosure Spain, S.L., Cynosure KK, Suzhou Cynosure Medical Devices, Co., Cynosure Mexico, Cynosure Korea Limited, Cynosure Pty Limited, Palomar Medical Technologies GmbH, Palomar Japan KK, and Cynosure B.V. All significant intercompany balances and transactions have been eliminated.
	Reclassifications
	Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation within the consolidated statements of operations.
	Cash, Cash Equivalents, Short and Long-Term Marketable Securities
	Cynosure considers all short-term, highly liquid investments with original maturities at the time of purchase of 90 days or less to be cash equivalents. Cynosure accounts for short and long-term marketable securities as available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments—Debt and Equity Securities Topic. Under ASC 320, securities purchased to be held for indefinite periods of time and not intended at the time of purchase to be held until maturity are classified as available-for-sale securities. ASC 320 requires Cynosure to recognize all marketable securities on the consolidated balance sheets at fair value. Cynosure’s marketable securities are stated at fair value based on quoted market prices. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive loss in shareholders’ equity. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. The cost of securities sold is determined by the specific identification method. Cynosure continually evaluates whether any marketable investments have been impaired and, if so, whether such impairment is temporary or other than temporary.
	Fair Value of Financial Instruments
	Cynosure’s financial instruments consist of cash, cash equivalents, short and long-term marketable securities, accounts receivable and capital leases. Cynosure’s estimate of fair value for financial instruments, other than marketable securities, approximates their carrying value at December 31, 2013 and 2012.
	ASC 820, Fair Value Measurement Topic, applies to all financial assets and financial liabilities that are being measured and reported on a fair value basis, establishes a framework for measuring fair value of assets and liabilities and expands disclosures about fair value measurements.
	Accounts Receivable and Concentration of Credit Risk
	Cynosure’s accounts receivable balance, net of allowance for doubtful accounts, was $36.6 million as of December 31, 2013, compared with $18.0 million as of December 31, 2012. The allowance for doubtful accounts as of December 31, 2013 and 2012 was $1.8 million and $2.0 million, respectively. Cynosure maintains an allowance for doubtful accounts based upon the aging of its receivable balances, known collectibility issues and Cynosure’s historical experience with losses. Cynosure works to mitigate bad debt exposure through its credit evaluation policies, reasonably short payment terms and geographical dispersion of sales. Cynosure’s revenue includes export sales to foreign companies located principally in Europe, the Asia/Pacific region and the Middle East. Cynosure obtains letters of credit for foreign sales that the Company considers to be at risk.
	No customer accounted for 10% or greater of revenue during 2013, 2012 or 2011. No customer accounted for 10% or greater of accounts receivable as of December 31, 2013 or 2012. Accounts receivable allowance activity consisted of the following for the years ended December 31:
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	2,043		$	1,872		$	2,207
	Additions		1,058			591			167
	Deductions		(1,298	)		(420	)		(502	)
	Balance at end of year	$	1,803		$	2,043		$	1,872
	Inventory
	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:
		December 31,
		2013			2012
		(In thousands)
	Raw materials	$	17,234		$	9,076
	Work in process		2,316			1,134
	Finished goods		34,548			22,696
		$	54,098		$	32,906
	Included in finished goods are lasers used for demonstration purposes. Cynosure’s policy is to include demonstration lasers as inventory for a period of up to one year after being used by the sales force at which time the demonstration lasers are either sold or transferred to fixed assets at the lower of cost or market and depreciated over their estimated useful life of three years. Similar to any other finished goods in inventory, Cynosure accounts for such demonstration inventory in accordance with the policy for excess and obsolescence review of Cynosure’s entire inventory.
	Cynosure’s excess and obsolescence reserve policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for products and market conditions. Cynosure regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining management’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted in the future. If inventory is determined to be overvalued, Cynosure recognizes such costs as cost of goods sold at the time of such determination. Although Cynosure performs a detailed review of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the value of Cynosure’s inventory and reported operating results.
	Cynosure purchases raw material components as well as certain finished goods from sole source suppliers. A delay in the production capabilities of these vendors could cause a delay in Cynosure’s manufacturing, and a possible loss of revenues, which would adversely affect operating results.
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Assets under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the respective lease term. Included in property and equipment are certain lasers that are used for demonstration purposes. Maintenance and repairs are charged to expense as incurred. Cynosure continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Cynosure evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Cynosure believes that, as of each of the balance sheet dates presented, none of Cynosure’s long-lived assets were impaired.
	Intangible Assets
	Cynosure capitalizes and includes in intangible assets the costs of developed technology and patents, customer relationships, trade names and business licenses. Intangible assets are recorded at fair value and stated net of accumulated amortization and impairments. Cynosure amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 5 to 23 years. Cynosure evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, Cynosure estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, Cynosure uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s remaining useful life is changed, Cynosure will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. Cynosure does not amortize its goodwill, but instead tests for impairment at least annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. Cynosure’s annual test for impairment occurs on the first day of its fourth quarter.
	Cynosure has adopted ASU 2011-08 Intangibles—Goodwill and Other, an amendment to ASC 350, which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.
	Cynosure has one reporting unit for goodwill impairment testing and has performed a qualitative assessment on that reporting unit. As a result of this assessment, the Company determined that goodwill is not impaired as of December 31, 2013.
	Revenue Recognition and Deferred Revenue
	Cynosure generates revenue from the sale of aesthetic treatment systems that are used by physicians and other practitioners to perform various non-invasive and minimally invasive aesthetic procedures. These systems incorporate a broad range of laser and other light-based energy sources. Cynosure offers service and warranty contracts in connection with these sales.
	Cynosure recognizes revenue from sales of aesthetic treatment systems and parts and accessories in accordance with the Revenue Recognition Topic ASC 605-10-S99. Cynosure recognizes revenue from sales of its treatment systems and parts and accessories upon delivery, provided there are no uncertainties regarding customer acceptance, there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectibility of the related receivable is reasonably assured. Revenues from the sales of service and warranty contracts are deferred and recognized on a straight-line basis over the contract period as services are provided. Payments received by Cynosure in advance of product delivery or performance of services are deferred until earned.
	Cynosure recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, Cynosure recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by Cynosure’s licensees occurred. Royalty revenues also include amounts due from settlements with licensees for back-owed royalties from prior periods. These settlement amounts are considered revenue, when collectability is reasonably assured, because they constitute Cynosure’s ongoing major or central operations.
	In December 2013, Cynosure completed a comprehensive settlement agreement with Tria Beauty, Inc. (“Tria”) which ended the patent infringement litigation between Tria and Palomar Medical Technologies, Inc. (“Palomar”). Under the agreement, Cynosure is entitled to receive $10.0 million plus future royalty payments. Cynosure will pay approximately $2.0 million of this revenue to Massachusetts General Hospital (“MGH”) under an exclusive license agreement between Palomar and MGH, which will be recorded as cost of revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $4.0 million of this revenue in the year ended December 31, 2013, which is recorded as royalty revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $1.0 million in cost of revenues in the year ended December 31, 2013 for legal and license fees related to this settlement.
	Multiple-element arrangements are evaluated in accordance with the principles of Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition Topic—Multiple Element Arrangements and Cynosure allocates revenue among the elements based upon each element’s relative fair value.
	In accordance with the provisions of ASC 605-45, Revenue Recognitions Topic—Principal Agent Considerations, Cynosure records shipping and handling costs billed to its customers as a component of revenue, and the underlying expense as a component of cost of revenue. Shipping and handling costs included as a component of revenue totaled approximately $0.6 million, $0.4 million, and $0.4 million for the years ended December 31, 2013, 2012 and 2011, respectively. Shipping and handling costs included as a component of cost of revenue totaled $0.6 million, $0.5 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Cynosure collects sales tax from its customers on product sales for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Cynosure presents its sales taxes on a net basis; therefore, these taxes are excluded from revenues.
	In 2013, most of the products and systems that Cynosure sells became subject to a new excise tax on sales of certain medical devices in the United States by the manufacturer, producer or importer in an amount equal to 2.3% of the sale price. These taxes are included within revenue and cost of revenues in Cynosure’s consolidated statement of operations.
	Cost of Revenues
	Cynosure’s cost of revenues consist primarily of material, labor and manufacturing overhead expenses and includes the cost of components and subassemblies supplied by third party suppliers. Cost of revenues also includes royalties incurred on certain products sold by Cynosure and its licensees, costs incurred in connection with Cynosure’s efforts to litigate or settle additional third party license agreements, service and warranty expenses, as well as salaries and personnel-related expenses, including stock-based compensation, for Cynosure’s operations management team, purchasing and quality control.
	Product Warranty Costs
	Cynosure typically provides a one-year parts and labor warranty on end-user sales of lasers. Distributor sales generally include a one-year warranty on parts only. Estimated future costs for initial product warranties are provided for at the time of revenue recognition. The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:
		Years Ended December 31,
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	3,415		$	3,171		$	2,112
	Warranty provision related to new sales		9,114			4,641			4,729
	Warranty provision assumed from acquisitions		1,422			—			342
	Costs incurred		(7,300	)		(4,397	)		(4,012	)
	Balance at end of year	$	6,651		$	3,415		$	3,171
Research and Development
Research and development costs consist of salaries and other personnel-related expenses, including stock-based compensation, of employees primarily engaged in research, development and engineering activities and materials used and other overhead expenses incurred in connection with the design and development of Cynosure’s products and from time to time expenses associated with collaborative research agreements that the Company may enter into. These costs are expensed as incurred.
In June 2009, Cynosure entered into a cooperative development agreement (“Agreement”) with Unilever Ltd. (“Unilever”) to develop and commercialize light-based devices for the emerging home use personal care market. Under the terms of this Agreement, Cynosure performs certain research and development activities to assist in the advancement of the commercialization of these devices, the cost of which is partially funded by Unilever. Cynosure incurred $0.5 million, $0.9 million, and $1.8 million of research and development costs in connection with this Agreement during fiscal 2013, 2012 and 2011, respectively, and recorded $0 million, $0.5 million, and $1.7 million of reimbursements from Unilever as a reduction to research and development expenses in the respective fiscal periods. In July 2012, Cynosure received FDA clearance in the United States to market the product in the United States. Unilever expects to launch the product commercially in the first half of 2014. Once the product is commercialized, Cynosure will be entitled to future royalty payments from Unilever.
Advertising Costs
Cynosure expenses advertising costs as incurred. Advertising costs totaled $1.1 million, $0.6 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Foreign Currency Translation
The financial statements of Cynosure’s foreign subsidiaries are translated from local currency into U.S. dollars using the current exchange rate at the balance sheet date for assets and liabilities, and the average exchange rate prevailing during the period for revenue and expenses. The functional currency for Cynosure’s foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Certain intercompany and third party foreign currency-denominated transactions generated foreign currency remeasurement gains (losses) of approximately $334,000, $360,000 and $(318,000) during 2013, 2012 and 2011, respectively, which are included in other income (expense), net, in the consolidated statements of operations.
Accumulated Other Comprehensive Loss
Changes to accumulated other comprehensive loss during the year ended December 31, 2013 were as follows (in thousands):
	Unrealized			Translation			Accumulated
	Gain on			Adjustment			Other
	Marketable						Comprehensive
	Securities, net						Loss
	of taxes
Balance—December 31, 2012	$	13		$	(1,612	)	$	(1,599	)
Current period other comprehensive gain		23			77			100
Balance—December 31, 2013	$	36		$	(1,535	)	$	(1,499	)
Stock-Based Compensation
Cynosure follows the fair value recognition provisions of ASC 718, Stock Compensation Topic (ASC 718). Cynosure expenses the fair value of stock options over the service period. ASC 718 requires companies to utilize an estimated forfeiture rate when calculating the expense for the period. Accordingly, Cynosure reviews its actual forfeiture rates and periodically aligns its stock compensation expense with the options that are vesting.
Cynosure recorded stock-based compensation expense of $3.7 million, $2.9 million and $2.6 million for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, respectively, Cynosure had $23,000 and $18,000 of stock-based compensation expense capitalized as a part of inventory.
Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective options, as follows:
	Years Ended December 31,
	2013			2012			2011
	(In thousands)
Cost of revenues	$	174		$	127		$	134
Sales and marketing		1,090			857			829
Research and development		594			495			446
General and administrative		1,830			1,431			1,152
Total stock-based compensation expense	$	3,688		$	2,910		$	2,561
As of December 31, 2013, there was $6.7 million of unrecognized compensation expense related to non-vested share awards that is expected to be recognized on a straight-line basis over a weighted average period of 1.37 years. Cash received from option exercises was $2.7 million, $7.2 million and $0.2 million during the years ended December 31, 2013, 2012 and 2011, respectively.
Cynosure granted 617,510, 405,790 and 411,104 stock options during the years ended December 31, 2013, 2012 and 2011, respectively. Cynosure uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair value of the options granted during the years ended December 31, 2013, 2012 and 2011 was $10.25, $9.23 and $7.26, respectively, using the following assumptions:
	Years Ended December 31,
	2013		2012	2011
Risk-free interest rate	0.33% - 1.49%		0.61% - 0.86%	0.87% - 2.37%
Expected dividend yield	—		—	—
Expected term	2 years - 4.8 years		5.8 years	5.8 years
Expected volatility	44% - 56%		56% - 57%	55% - 57%
Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Cynosure’s estimated expected stock price volatility is based on its own historical volatility for the 2013, 2012 and 2011 periods. Cynosure’s expected term of options granted during the year ended December 31, 2013 represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and Cynosure’s historical exercise patterns. Cynosure’s expected term of options granted during the years ended December 31, 2012 and 2011 was derived from the simplified method described in ASC 718-10-S99. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield of zero is based on the fact that Cynosure has never paid cash dividends and has no present intention to pay cash dividends.
Interest (Expense) Income, net
Interest (expense) income consists primarily of interest charges on capital lease obligations, and interest earned on Cynosure’s short and long-term marketable securities consisting of state and municipal bonds, U.S. government agencies and treasuries, corporate obligations and commercial paper. Cynosure expects interest expense to increase in 2014 as a result of interest charges incurred on the buildings portion of its U.S. operating facility.
Income Taxes
Cynosure provides for income taxes in accordance with ASC 740, Accounting for Income Taxes (ASC 740). ASC 740 recognizes tax assets and liabilities for the cumulative effect of all temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities, and are measured using the enacted tax rates that will be in effect when these differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
Cynosure accounts for uncertain tax positions following the provisions of ASC 740. ASC 740 clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Net (Loss) Income per Common Share
Basic net (loss) income per share is determined by dividing net (loss) income by the weighted average common shares outstanding during the period. Diluted net (loss) income per share is determined by dividing net (loss) income by the diluted weighted average shares outstanding during the period. Diluted weighted average shares reflect the dilutive effect, if any, of common stock options based on the treasury stock method. For the year ended December 31, 2013 and 2012, there are no outstanding Class B shares, and Cynosure may not issue Class B shares in the future. For the years ended December 31, 2011, common shares outstanding include both Class A and Class B as each share participated equally in earnings. Class B shares were convertible at any time into shares of Class A on a one-for-one basis at the option of the holder.
The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011 is as follows (in thousands, except per share data):
	Years Ended December 31,
	2013			2012			2011
Net (loss) income	$	(1,647	)	$	10,961		$	(2,905	)
Basic weighted average common shares outstanding		19,325			13,189			12,585
Weighted average common stock equivalents		—			603			—
Diluted weighted average common shares outstanding		19,325			13,792			12,585
Basic net (loss) income per share	$	(0.09	)	$	0.83		$	(0.23	)
Diluted net (loss) income per share	$	(0.09	)	$	0.79		$	(0.23	)
For the year ended December 31, 2013, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2013, outstanding options to purchase 1.3 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
For the year ended December 31, 2012, options to purchase approximately 0.7 million shares of Cynosure’s Class A common stock were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.
For the year ended December 31, 2011, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2011, outstanding options to purchase 2.0 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
Recent Accounting Pronouncements
In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. Under this ASU, an entity is required to provide information about the amounts reclassified out of Accumulated Other Comprehensive Income (AOCI) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. ASU 2013-02 is effective for interim and annual periods beginning after December 15, 2012. The adoption of this guidance did not materially impact Cynosure’s financial statements or disclosures.

Fair_Value

Fair Value	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value	'
	3. Fair Value
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable markets data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2013 (in thousands):
			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	5,185	$	—	$	—	$	5,185
	State and municipal bonds(2)		$	—		18,133	$	—		18,133
	Treasuries and government agencies			—		15,028		—		15,028
	Corporate obligations and commercial paper			—		3,020		—		3,020
	Equity securities			49		—		—		49
	Total		$	5,234	$	36,181	$	—	$	41,415
	-1	Included in cash and cash equivalents at December 31, 2013.
	-2	$0.8 million included in cash and cash equivalents at December 31, 2013.

Short_and_LongTerm_Marketable_

Short and Long-Term Marketable Securities	12 Months Ended
	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Short and Long-Term Marketable Securities	'
	4. Short and Long-Term Marketable Securities
	Cynosure’s available-for-sale securities at December 31, 2013 consist of approximately $36.2 million in investments in debt securities consisting of state and municipal bonds, treasuries and government agencies, corporate obligations and commercial paper and approximately $49,000 in equity securities. All investments in available-for-sale securities are recorded at fair market value, with any unrealized gains and losses reported as a separate component of accumulated other comprehensive loss. As of December 31, 2013, Cynosure’s marketable securities consist of the following (in thousands):
		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-Sale Securities:
	Cash equivalents:
	State and municipal bonds	$	793	$	793	$	—	$	—
	Total cash equivalents	$	793	$	793	$	—	$	—
	Short-term marketable securities:
	State and municipal bonds	$	10,552	$	10,551	$	1	$	—
	Treasuries and government agencies		15,028		15,018		10		—
	Corporate obligations and commercial paper		1,004		1,004		—		—
	Equity securities		49		8		41		—
	Total short-term marketable securities	$	26,633	$	26,581	$	52	$	—
	Long-term marketable securities:
	State and municipal bonds	$	6,788	$	6,787	$	1	$	—
	Corporate obligations and commercial paper		2,016		2,015		1		—
	Total long-term marketable securities	$	8,804	$	8,802	$	2	$	—
	Total available-for-sale securities	$	36,230	$	36,176	$	54	$	—
	Total marketable securities	$	35,437
	As of December 31, 2012, Cynosure’s marketable securities consist of the following (in thousands):
		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-sale Securities:
	Cash equivalents:
	State and municipal bonds	$	4,417	$	4,417	$	—	$	—
	Government agencies	$	1,000	$	1,000	$	—	$	—
	Total cash equivalents	$	5,417	$	5,417	$	—	$	—
	Short-term marketable securities:
	State and municipal bonds	$	33,250	$	33,251	$	6	$	(7	)
	Treasuries and government agencies		7,346		7,345		1		—
	Equity securities		21		6		15		—
	Total short-term marketable securities	$	40,617	$	40,602	$	22	$	(7	)
	Long-term marketable securities:
	State and municipal bonds	$	18,046	$	18,052	$	2	$	(8	)
	Treasuries and government agencies		2,025		2,021		4		—
	Total long-term marketable securities	$	20,071	$	20,073	$	6	$	(8	)
	Total available-for-sale securities	$	66,105	$	66,092	$	28	$	(15	)
	Total marketable securities	$	60,688
	As of December 31, 2013, Cynosure’s available-for-sale debt securities mature as follows (in thousands):
				Maturities
		Total		Less Than One Year		One to Five Years		More than five years
	State and municipal bonds	$	18,133	$	11,345	$	6,788	$	—
	Treasuries and government agencies		15,028		15,028		—		—
	Corporate obligations and commercial paper		3,020		1,004		2,016		—
	Total available-for-sale debt securities	$	36,181	$	27,377	$	8,804	$	—

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisition	'
	5. Acquisition
	Palomar Medical Technologies, Inc.
	On June 24, 2013, Cynosure acquired Palomar. The acquisition has complemented and broadened Cynosure’s product lineup with the addition of Palomar’s intense pulsed light, fractional laser and diode aesthetic systems, doubled the number of patents in Cynosure’s portfolio and enhanced Cynosure’s global distribution network. As a result of the transaction, former Palomar stockholders, in the aggregate, received for their shares of Palomar common stock $145.8 million in cash and 6.0 million shares of Cynosure Class A common stock. The total consideration was valued at $287.2 million, based upon the closing price of Cynosure Class A common stock on June 24, 2013. This acquisition was considered a business acquisition for accounting purposes. The goodwill recognized is attributable to synergies associated with the Palomar technology which has been integrated with Cynosure’s product portfolio and distributed throughout the U.S. and international distribution channels.
	Cynosure has retained an independent valuation firm to assess the fair value of the identifiable intangible assets and certain tangible assets acquired, and is also currently assessing the fair value of other assets acquired and liabilities assumed. Pro forma financial information was filed with the SEC within the applicable time period. Cynosure has preliminarily allocated the purchase price to the net tangible and intangible assets based on their estimated fair values as of June 24, 2013. As such, the fair value of the assets acquired and liabilities assumed presented in the table below are provisional and will be finalized in a later period once the fair value procedures are completed. During the fourth quarter of 2013, Cynosure revised its estimates (in thousands) of the assets acquired and liabilities assumed in regards to the acquisition of Palomar, and as a result, reduced goodwill from $90,856 at September 30, 2013 to $79,345 at December 31, 2013. Intangible assets increased by $12,020, due to a revised estimate received from the independent valuation firm. Accounts receivable increased by $1,813, due primarily to a reduction in bad debt reserves along with the recognition of a royalty receivable. Inventory decreased by $1,609, due primarily to adjustments to the inventory reserve and the reclassification of demonstration equipment to fixed assets, per Cynosure policy. Fixed assets decreased by $530, due to a downward revision in the demonstration equipment acquired. Other assets decreased by $200, due to a write-off of certain other assets acquired. Accrued expenses increased by $1,359, due primarily to additional accruals related to the opening balance sheet. Deferred revenue increased by $518, due primarily to the payment of certain service contracts during the year that were unpaid as of the opening balance sheet date. Deferred tax liability and other long-term liabilities decreased by $1,894, primarily due to the reclass of certain tax reserves.
	The allocation of the acquisition purchase price is subject to adjustment upon finalization of the fair value procedures, and therefore the current measurements of inventory, intangible assets acquired, goodwill, accrued warranty and deferred tax assets and liabilities (including uncertain tax positions) are subject to change.
	The following table summarizes the purchase price allocation, net of $117.9 million in cash, cash equivalents and marketable securities acquired (in thousands):
	Purchase price:
	Cash and stock paid	$	287,204
	Cash, cash equivalents and marketable securities acquired		(117,929	)
	Purchase price, net	$	169,275
	Assets (liabilities) acquired:
	Accounts receivable		11,761
	Inventory		20,054
	Prepaids and other assets		722
	Property and equipment		30,639
	Other assets		132
	Intangible assets		52,340
	Goodwill		79,345
	Accounts payable		(7,269	)
	Accrued expenses		(9,771	)
	Deferred revenue		(3,528	)
	Deferred tax liability		(5,150	)
	Total	$	169,275
	The amounts included in revenue within the consolidated statement of operations, relating to the acquisition of Palomar, for the year ended December 31, 2013 was $50.8 million. As a result of the integration of the operations of Palomar into Cynosure’s operations, disclosures of earnings included in the accompanying consolidated statement of operations since the acquisition date is not practicable.
	The following unaudited pro forma condensed consolidated operating results for the years ended December 31, 2013 and 2012 summarize the combined results of operations for Cynosure and Palomar. The unaudited pro forma condensed consolidated operating results includes the business combination accounting effects as if the acquisition had been completed as of January 1, 2012 (for both the 2013 and 2012 period results) after giving effect to certain adjustments. These pro forma financial statements are for informational purposes only and are not necessarily indicative of the operating results that would have occurred if the transaction had occurred on such date. No effect has been given for synergies, if any, that may be realized through the acquisition.
		Year Ended
		December 31,
		2013			2012
	Revenue (unaudited, in thousands)	$	267,941		$	231,153
	Pre-tax income (loss) (unaudited, in thousands)	$	12,452		$	(42,199	)
	The unaudited consolidated pro forma financial information above includes significant, non-recurring adjustments made to account for certain costs which would have been incurred if the acquisition had been completed on January 1, 2012, including $24.2 million in change of control severance payments and $2.4 million associated with the step up in fair value of finished goods inventory acquired through the acquisition.
	During the year ended December 31, 2013, Cynosure incurred $32.4 in selling, research and development, general and administrative costs associated with the acquisition of Palomar. In connection with the acquisition of Palomar, certain terminated Palomar employees were, and certain continuing Palomar employees are, entitled to severance benefits in specified circumstances associated with the change of control of Palomar. In connection with the acquisition and these change of control severance arrangements, Cynosure incurred $24.2 million of compensation expense during the year ended December 31, 2013. Cynosure expects to incur an additional $0.5 million of compensation expense during each of the first two quarters of 2014 in connection with these change in control severance payments. Costs associated with the acquisition of Palomar are primarily recorded in the general and administrative expenses within the consolidated statement of operations.
	During the year ended December 31, 2013, Cynosure incurred $0.6 million in equity issuance costs associated with the acquisition of Palomar. These amounts were recorded to additional paid-in capital.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	6. Goodwill and Other Intangible Assets
	Changes to goodwill during the year ended December 31, 2013 were as follows (in thousands):
	Balance—December 31, 2012	$	15,811
	Palomar acquisition		79,345
	Translation adjustment		27
	Balance—December 31, 2013	$	95,183
	Other intangible assets consist of the following at December 31, 2013 and December 31, 2012 (in thousands):
		Developed			Business			Customer			Trade			Other			Total
		Technology			Licenses			Relationships			Names
		& Patents
	December 31, 2013
	Cost	$	27,510		$	384		$	15,833		$	16,930		$	1,338		$	61,995
	Translation adjustment		—			40			26			—			4			70
	Accumulated amortization		(2,216	)		(239	)		(3,662	)		(761	)		(8	)		(6,886	)
	Balance, December 31, 2013	$	25,294		$	185		$	12,197		$	16,169		$	1,334		$	55,179
	December 31, 2012
	Cost	$	3,250		$	384		$	3,323		$	2,650		$	48		$	9,655
	Translation adjustment		—			38			24			—			3			65
	Accumulated amortization		(1,292	)		(195	)		(2,019	)		(272	)		(5	)		(3,783	)
	Balance, December 31, 2012	$	1,958		$	227		$	1,328		$	2,378		$	46		$	5,937
	Cynosure acquired $52.3 million of identifiable intangible assets in the Palomar acquisition, of which $24.2 million was assigned to technology patents, $12.5 million was assigned to customer relationships, $14.3 million was assigned to trademarks and $1.3 million was assigned to in-process research and development. The technology patents are being amortized on an accelerated basis over a 6.8 year weighted-average amortization period; the customer relationships are being amortized on an accelerated basis over a 12.5 year weighted-average amortization period; the trademarks are being amortized on a straight-line basis over a 22.5 year weighted-average amortization period; and the in-process research and development is an indefinite-life intangible asset. In total, the weighted-average amortization period for these intangible assets is 12.3 years.
	Cynosure is currently evaluating the fair value of assets acquired and liabilities assumed from the Palomar acquisition, including identifiable intangible assets and their related amortization periods. As such, the $52.3 million in intangible assets presented in the table above are provisional and will be finalized in a later period once the fair value procedures are completed.
	Amortization expense related to developed technology and patents is classified as a component of cost of revenues. Amortization expense related to customer relationships and trade names is classified as a component of amortization of intangible assets acquired. Amortization expense related to business licenses and other is classified as a component of general and administrative expenses. For the year ended December 31, 2013, Cynosure recognized $1.3 million in amortization expense, classified as a component of amortization of intangible assets acquired, related to the identifiable intangible assets from the Palomar acquisition. For the year ended December 31, 2013, Cynosure recognized $0.5 million in amortization expense, classified as a component of cost of revenues, related to the identifiable intangible assets from the Palomar acquisition.
	Amortization expense for the years ended December 31, 2013, 2012 and 2011 was $3.1 million, $1.9 million and $1.2 million, respectively. Cynosure has approximately $1.3 million of indefinite-life intangible assets that are included in other intangible assets in the table above. As of December 31, 2013, amortization expense on existing intangible assets for the next five years and beyond is as follows (table in thousands):
	2014	$	8,375
	2015		8,397
	2016		7,616
	2017		5,677
	2018		4,222
	2019 and Thereafter		19,561
	Total	$	53,848
	The table above includes $2.9 million for 2014, $2.5 million for 2015, $2.1 million for 2016, $2.0 million for 2017, $1.9 million for 2018 and $17.0 million for 2019 and thereafter, to be recognized within operating expenses related to intangible assets acquired through the Palomar, Eleme Medical and ConBio acquisitions, with the remainder recognized within cost of revenues.

Segment_and_Geographic_Informa

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment and Geographic Information	'
	7. Segment and Geographic Information
	In accordance with ASC 280, Segment Reporting Topic, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Cynosure’s chief decision-maker, as defined under ASC 280, is a combination of the Chief Executive Officer and the Chief Financial Officer. Cynosure views its operations and manages its business as one segment, aesthetic treatment products and services.
	The following table represents total revenue by geographic destination:
		Year Ended December 31,
		2013			2012			2011
		(In thousands)
	United States	$	111,179		$	72,704		$	43,903
	Europe		39,529			28,808			27,918
	Asia/Pacific		52,574			39,991			27,357
	Other		22,728			11,990			11,424
		$	226,010		$	153,493		$	110,602
	Total assets by geographic area are as follows:
		December 31,
		2013			2012
		(In thousands)
	United States	$	390,941		$	210,596
	Europe		15,916			15,623
	Asia/Pacific		11,496			11,038
	Eliminations		(3,859	)		(2,688	)
		$	414,494		$	234,569
	Long-lived assets by geographic area are as follows:
		December 31,
		2013			2012
		(In thousands)
	United States	$	24,120		$	7,266
	Europe		2,403			1,570
	Asia/Pacific		1,600			432
		$	28,123		$	9,268
	No individual country within Europe or Asia/Pacific represented greater than 10% of total revenue, total assets or total long-lived assets for any period presented.

Balance_Sheet_Accounts

Balance Sheet Accounts	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Balance Sheet Accounts	'
	8. Balance Sheet Accounts
	Property and Equipment
	Property and equipment consists of the following at December 31:
			Estimated		2013			2012
			Useful		Cost			Cost
			Life
			(Years)
			(In thousands)
	Equipment			5-Mar	$	7,835		$	5,098
	Furniture and fixtures			5-Mar		2,698			1,982
	Computer equipment and software			3		5,047			3,796
	Leased Equipment			4-Mar		1,660			1,774
	Leased Buildings			14		13,327			—
	Leasehold improvements			5		2,898			2,504
	Demonstration equipment			3		24,094			20,095
	Construction in-progress					495			571
						58,054			35,820
	Less: Accumulated depreciation and amortization					(31,609	)		(27,613	)
					$	26,445		$	8,207
	Depreciation expense relating to property and equipment was $6.0 million, $5.0 million and $5.7 million for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, the cost of assets recorded under capitalized leases was approximately $15.0 million and $1.8 million, respectively, and the related accumulated amortization was approximately $1.2 million and $0.9 million, respectively. Amortization expense of assets recorded under capitalized leases is included as a component of depreciation expense.
	Long-Lived Assets Held for Sale
	In accordance with ASC 360, Cynosure considers properties to be assets held for sale when all of the following criteria are met:
		•		management commits to a plan to sell a property;
		•		the property is available for immediate sale in its present condition;
		•		an active program to locate a buyer and other actions required to complete the plan to sell the asset have been initiated;
		•		sale of the property is probable and Cynosure expects the completed sale will occur within one year;
		•		the property is actively being marketed for sale at a price that is reasonable given its current market value; and
		•		it is unlikely that the disposal plan will be significantly modified or discontinued.
	Upon designation as an asset held for sale, Cynosure records the carrying value of each property at the lower of its carrying value or its estimated fair value, less estimated costs to sell, and Cynosure ceases depreciation as of the date the asset is classified as held for sale.
	Effective June 24, 2013, as part of the acquisition of Palomar, Cynosure acquired the land and building at 15 Network Drive in Burlington, MA. In early September 2013, Cynosure began to market the land and building. Cynosure received a letter of intent from a potential buyer dated October 7, 2013. Given these facts and circumstances, Cynosure has concluded that it had met the requirements to classify the land and building in Burlington, MA as held for sale as of September 1, 2013.
	In November, 2013, Cynosure completed the sale of the former Palomar headquarters. Proceeds of the sale, after transaction costs, were approximately $25.1 million. During the year ended December, 31, 2013, Cynosure incurred a loss of $0.6 million resulting from the sale of the land and building. This loss is recorded in the general and administrative expenses within the consolidated statement of operations.
	Accrued Expenses
	Accrued expenses consist of the following at December 31:
			2013		2012
			(In thousands)
	Accrued payroll and taxes		$	9,547	$	3,039
	Accrued employee benefits			2,093		1,149
	Accrued warranty costs			6,651		3,415
	Accrued commissions			5,243		2,620
	Accrued other			13,443		6,978
			$	36,977	$	17,201
	Other Noncurrent Liabilities
	Other noncurrent liabilities consist of the following at December 31:
			2013		2012
			(In thousands)
	Noncurrent deferred rent		$	2	$	1,473
	Noncurrent deferred tax liability			8,512		473
	Noncurrent income tax reserve			51		319
			$	8,565	$	2,265

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	9. Related Party Transactions
	As of December 31, 2013, El.En. S.p.A. (“El.En.”) beneficially owned 2,098,628 shares, or approximately 10%, of Cynosure’s outstanding common stock. Purchases of inventory from El.En. during the years ended December 31, 2013, 2012 and 2011 were approximately $4.7 million, $5.8 million and $7.8 million, respectively. As of December 31, 2013 and 2012, amounts due to related party for these purchases were approximately $1.3 million and $1.9 million, respectively. There were no amounts due from El.En. as of December 31, 2013 or 2012.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	10. Stockholders’ Equity
	Common Stock Authorized
	Cynosure has a dual-class capital structure consisting of $0.001 par value Class A common stock and Class B common stock. Cynosure has authorized 61,500,000 shares of $0.001 par value Class A common stock and 8,500,000 shares of $0.001 par value Class B common stock.
	In 2012, Cynosure completed a public offering pursuant to which Cynosure issued and sold 2,840,000 shares of its Class A common stock, and El.En. sold 840,000 shares of its Class A common stock. In connection with the closing of the offering, all outstanding shares of Class B common stock converted on a one-for-one basis into shares of Class A common stock. As a result, there are no longer any shares of Cynosure’s Class B common stock issued or outstanding, and Cynosure may not issue shares of Class B common stock in the future.
	As of December 31, 2013, there were 22,632,749 shares of Class A common stock and no shares of Class B common stock issued.
	The rights, preferences and privileges of Class A common stock are as follows:
	Voting Rights
	The holders of Class A common stock will be entitled to one vote per share with respect to each matter presented to Cynosure stockholders on which the holders of common stock are entitled to vote.
	Conversion
	Cynosure’s Class A common stock is not convertible into any other shares of Cynosure’s capital stock.
	Dividends
	Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Class A common stock shall be entitled to share equally, on a per share basis, in any dividends that Cynosure’s board of directors may determine to issue from time to time.
	Liquidation Rights
	In the event of Cynosure’s liquidation or dissolution, the holders of Class A common stock shall be entitled to share equally, on a per share basis, in all assets remaining after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.
	Preferred Stock
	Cynosure has authorized 5,000,000 shares of $0.001 par value preferred stock. The Board of Directors has full authority to issue this stock and to fix the voting powers, preference rights, qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, redemption privileges and liquidation preferences and the number of shares constituting any series or designation of such series.
	Treasury Stock
	On October 29, 2013, Cynosure announced that its board of directors authorized the repurchase of up to $25 million of its Class A common stock, from time to time, on the open market or in privately negotiated transactions under a stock repurchase program. The program will terminate upon the purchase of $25 million in common stock or expiration of the program on November 1, 2015. During the year ended December 31, 2013, Cynosure repurchased 653,301 shares of its common stock at an aggregate cost of $15.4 million and at a weighted average price of $23.54 per share under this program. As of December 31, 2013, Cynosure has repurchased an aggregate of 886,407 shares under this program and previous programs at an aggregate cost of $17.6 million.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	11. Stock-Based Compensation
	2004 Stock Option Plan
	In October 2004, the Board of Directors adopted and the stockholders approved the 2004 Stock Option Plan (the 2004 Plan). The 2004 Plan provided for the grant of ISOs, as well as nonstatutory options. The Board of Directors administers the 2004 Plan and had sole discretion to grant options to purchase shares of Cynosure’s common stock.
	The Board of Directors determines the term of each option, option price, number of shares for which each option is granted, whether restrictions would be imposed on the shares subject to options and the rate at which each option is exercisable. The exercise price for options granted is determined by the Board of Directors, except that for ISOs, the exercise price could not be less than the fair market value per share of the underlying common stock on the date granted (110% of fair market value for ISOs granted to holders of more than 10% of the voting stock of Cynosure). The term of the options is set forth in the applicable option agreement, except that in the case of ISOs, the option term cannot exceed ten years. Options granted under the Plan vested either (i) over a 48-month period at the rate of 25% after the first year and 6.25% each quarter thereafter until fully vested or (ii) over a vesting period determined by the Board of Directors. As of December 31, 2013, there were no shares available for future grant under the 2004 Plan.
	2005 Stock Incentive Plan
	In August 2005, the Board of Directors adopted the 2005 Stock Incentive Plan (the 2005 Plan), which was approved by Cynosure’s stockholders in December 2005. The 2005 Plan provided for the grant of ISOs, as well as nonstatutory options. The Board of Directors administers the 2005 Plan and has sole discretion to grant options to purchase shares of Cynosure’s common stock.
	The Board of Directors determines the term of each option, option price, number of shares for which each option is granted, whether restrictions would be imposed on the shares subject to options and the rate at which each option is exercisable. The exercise price for options granted is determined by the Board of Directors, except that for ISOs, the exercise price could not be less than the fair market value per share of the underlying common stock on the date granted (110% of fair market value for ISOs granted to holders of more than 10% of the voting stock of Cynosure). The term of the options is set forth in the applicable option agreement, except that in the case of ISOs, the option term cannot exceed ten years. At December 31, 2013 the number of shares of Class A common stock reserved for issuance under the 2005 Plan is 5,588,369 shares. Options granted under the Plan vest either (i) over a 36-month period at the rate of 8.33% each quarter until fully vested or (ii) over a vesting period determined by the Board of Directors. In April 2013, the number of shares of Class A common stock reserved for issuance under the 2005 Plan increased by 2,500,000 shares in accordance with the terms of the plan. As of December 31, 2013, there are 2,277,659 shares available for future grant under the 2005 Plan.
	Stock option activity under the 2004 Plan and the 2005 Plan is as follows:
		Number of			Exercise Price		Weighted-		Weighted-		Aggregate
		Options			Range		Average		Average		Intrinsic
							Exercise		Remaining		Value
							Price		Contractual		(in thousands)
									Life
	Vested		1,424,788			3.00 - 36.94		16.2				11,890
	Unvested		527,823			9.56 - 24.99		16.15				4,224
	Outstanding, December 31, 2012		1,952,611		$	3.00 - $36.94	$	16.18		6.49 years	$	16,114
	Granted		617,510			22.12 - 28.68		25.73				1,184
	Exercised		(202,603	)		3.00 - 21.73		13.43				2,345
	Forfeited		(63,652	)		6.78 - 36.94		22.63				293
	Outstanding, December 31, 2013		2,303,866		$	3.00 - $36.94	$	18.81		6.51 years	$	19,046
	Vested		1,596,565			3.00 - 36.94		16.93		5.35 years		16,061
	Unvested		707,301			9.56 - 28.68		23.06		9.13 years		2,985
	Vested or expected to vest, December 31, 2013		2,285,851		$	3.00 - $36.94	$	18.75		6.49 years	$	19,008
	Exercisable, December 31, 2013		1,596,565		$	3.00 - $36.94	$	16.93		5.35 years	$	16,061

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	12. Income Taxes
	(Loss) income before income tax (benefit) provision consists of the following:
		2013			2012			2011
		(In thousands)
	Domestic	$	(8,633	)	$	10,344		$	(2,710	)
	Foreign		3,096			2,381			612
	Total	$	(5,537	)	$	12,725		$	(2,098	)
	The (benefit) provision for income taxes consists of:
		2013			2012			2011
		(In thousands)
	Current:
	Federal	$	732		$	1,382		$	241
	State		214			128			179
	Foreign		890			606			433
	Total current		1,836			2,116			853
	Deferred:
	Federal		(5,406	)		152			—
	State		(304	)		—			—
	Foreign		(16	)		(504	)		(46	)
	Total deferred		(5,726	)		(352	)		(46	)
		$	(3,890	)	$	1,764		$	807
	A reconciliation of the federal statutory rate to Cynosure’s effective tax rate is as follows for the years ended December 31:
		2013			2012			2011
	Income tax provision at federal statutory rate:		35	%		35	%		35	%
	Increase (decrease) in tax resulting from -
	State taxes, net of federal benefit		(3.1	)		0.7			(8.9	)
	Nondeductible expenses		(11.9	)		2.1			(12.1	)
	Tax-exempt interest income		0.5			(0.3	)		1.4
	Effect of foreign taxes		2.7			(1.8	)		3.6
	Stock-based compensation		(0.1	)		(0.9	)		(0.6	)
	Research and development credit		25.8			—			23.9
	Change in uncertain tax positions		4.8			2.5			—
	Change in valuation allowance		162			(20.5	)		(81.5	)
	Change in control payments		(128.8	)		—			—
	Transaction costs		(13.6	)		—			—
	Other		(3.1	)		(2.9	)		0.7
	Effective income tax rate		70.2	%		13.9	%		(38.5	)%
	In 2013, the Company recorded an income tax benefit of $3.9 million, representing an effective tax rate of 70%. The difference between the statutory tax rate and the effective tax rate was primarily attributable to a non-recurring benefit of $5.6 million for the release of a portion of the domestic valuation allowance due to taxable temporary differences available as a source of income to realize the benefit of certain pre-existing Cynosure deferred tax assets as a result of the Palomar acquisition. Excluding this item, the tax provision for the year ended December 31, 2013 would have been $1.7 million. Other factors resulting in differences between the statutory tax rate and effective tax rate are the jurisdictional mix of earnings, valuation allowance maintained against a portion of its U.S. and certain foreign deferred tax assets, non-deductible expenses (primarily related to change in control payments such as golden parachute payments made to Palomar executives and transaction costs) and tax credits.
	Significant components of Cynosure’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		2013			2012
		(In thousands)
	Deferred tax assets:
	Accrued expenses and reserves	$	9,747		$	2,741
	Domestic net operating loss & tax credit carry-forwards		19,925			1,692
	Foreign net operating loss carry-forwards		2,022			682
	Stock-based compensation		6,020			5,620
	Capital leases		5,472			—
	Intangible assets		—			520
	Other deferred tax assets		1,636			1,854
	Gross deferred tax assets	$	44,822		$	13,109
	Valuation allowance		(19,186	)		(11,804	)
	Total deferred tax assets (after valuation allowance)	$	25,636		$	1,305
	Long-term deferred tax liabilities:
	Intangible assets	$	(18,227	)	$	—
	Fixed assets		(5,463	)		(387	)
	Other deferred tax liabilities		(534	)		—
	Total long-term deferred tax liabilities	$	(24,224	)	$	(387	)
	Net deferred tax assets	$	1,412		$	918
	The valuation allowance increased by $7.4 million during 2013, primarily due to the establishment of valuation allowances in purchase accounting against acquired Palomar deferred assets and on current year operating losses generated in foreign jurisdictions that the Company has determined are not more-likely-than-not realizable. This increase in valuation allowance was partially offset by a decrease in the valuation allowance associated with a non-recurring benefit for the release of a portion of the domestic valuation allowance due to taxable temporary differences available as a source of income to realize the benefit of certain pre-existing Cynosure deferred tax assets as a result of the Palomar acquisition, and the utilization of domestic tax attributes against which a valuation allowance had been maintained to offset current year income. As of December 31, 2013, Cynosure has a partial valuation allowance on the net deferred tax assets in the United States as it has benefitted its U.S. deferred tax assets to the extent it has taxable income in a carryback year and existing taxable temporary differences. A full valuation allowance is maintained on the net deferred tax assets of its subsidiaries in Japan, Mexico and Australia as well as Palomar Spain and Palomar Germany.
	At December 31, 2013, Cynosure has domestic federal net operating loss carry-forwards of approximately $41.2 million, state net operating loss carry-forwards of $4.7 million, federal tax credit carry-forwards of $7.3 million and state tax credit carry-forwards of $1.7 million that are available to reduce future taxable income. Utilization of the net operating losses and tax credits acquired as a result of the Palomar acquisition are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 381, 382 and 383. At December 31, 2013, $0.4 million of the federal net operating loss carry-forwards, $2.3 million of the state net operating loss carry-forwards, $1.1 million of the federal tax credit carry-forwards and $0.1 million of the state tax credit carry-forwards relate to excess stock based compensation tax deductions for which the benefit will be recorded to additional paid-in capital when recognized. The federal and state net operating losses begin to expire in 2020 and 2014, respectively. The federal and state tax credits begin to expire in 2018.
	At December 31, 2013, Cynosure has foreign net operating losses of approximately $6.1 million in Germany, Mexico, Australia, Japan, and Spain that are available to reduce future income. Foreign net operating losses in Germany and Australia do not expire. Mexican and Japanese net operating losses will begin to expire in 2019. Spanish net operating losses will begin to expire in 2029. Income taxes have not been provided on the undistributed earnings of foreign subsidiaries of approximately $13.6 million, because such earnings are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as Cynosure’s subsidiaries continue to expand their operations, to service existing obligations and to fund future foreign acquisitions. Cynosure does not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations.
	ASC 740, Accounting for Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement of a tax position taken or expected to be taken in a tax return.
	The aggregate changes in gross unrecognized tax benefits during the years ended December 31, 2013, 2012 and 2011 were as follows (in thousands):
	2013			2012			2011
Balance at beginning of year	$	586		$	—		$	—
Increases for tax positions taken during current period		76			398			—
Increases for tax positions taken in prior periods		—			188			—
Increases for acquired tax positions taken in prior periods		1,625			—			—
Decreases for tax positions taken in prior periods		(398	)		—			—
Decreases for lapse in statutes		(188	)		—			—
Balance at end of year	$	1,701		$	586		$	—
At December 31, 2013, Cynosure had gross tax-effected unrecognized tax benefits of $1.7 million of which $0.1 million, if recognized, would favorably impact the effective tax rate. At December 31, 2012, Cynosure had gross tax-effected unrecognized tax benefits of $0.6 million, of which $0.3 million, if recognized, would favorably impact the effective tax rate. Cynosure classifies interest and penalties related to income taxes as a component of its provision for income taxes, and the amount of interest and penalties recorded as of December 31, 2013 and 2012 in the statements of operations and balance sheet was immaterial. The Company does not expect any material changes in the amounts of unrecognized tax benefits over the next 12 months.
Cynosure files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Cynosure is no longer subject to U.S. federal tax examinations for years prior to 2010. With few exceptions, Cynosure is no longer subject to U.S. state and local income tax examinations by tax authorities for years before 2009. Additionally, certain non-U.S. jurisdictions are no longer subject for income tax examinations by tax authorities for years before 2009.

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2013
Postemployment Benefits [Abstract]	'
401(k) Plan	'
	13. 401(k) Plan
	Cynosure sponsors the Cynosure 401(k) defined contribution plan. Participation in the plan is available to all employees of Cynosure who meet certain eligibility requirements. The Plan is qualified under Section 401(k) of the Internal Revenue Code, and is subject to contribution limitations as set annually by the Internal Revenue Service. Employer matching contributions are at Cynosure’s discretion. Cynosure’s contributions to this plan totaled approximately $579,000, $419,000 and $357,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	14. Commitments and Contingencies
	Lease Commitments
	On November 18, 2013, Cynosure entered into the Lease Amendment related to its headquarters located at 5 Carlisle Road, Westford, MA. Pursuant to the Lease Amendment, the term of the Lease has been extended to May 2027 (with two five-year extension options) and the leased premises have been expanded to include additional space at the current location as well as space in the adjacent building, 3 Carlisle Road, Westford, MA. Under the terms of the Lease Amendment, the base rent under the Lease will be abated for a 21-month period beginning in May 2014, and Cynosure will have rights to lease additional space at 3 Carlisle Road.
	ASC 840, Leases, establishes the framework for accounting for the Amendment. In accordance with ASC 840, Cynosure is accounting for the land portion of the leased premises as an operating lease. The buildings at 5 Carlisle Road and 3 Carlisle Road have met the criteria for capital lease accounting under ASC 840-10-25-1, and thus Cynosure is accounting for the buildings portion of the leased premises as capital leases and incurring interest charges accordingly. The interest rates used for the 5 Carlisle Road and 3 Carlisle Road capital leases are 10.8% and 8.8%, respectively. The expansion of the leased premises, as well as improvements to the leased premises, are recorded on the balance sheet as leasehold improvements within property, plant and equipment. Assets under capital leases and leasehold improvements related to the Amendment are amortized using the straight-line method over the respective lease term.
	Cynosure leases the land portion of its U.S. operating facility and certain foreign facilities under noncancelable operating lease agreements expiring through May 2027. These leases are non-cancellable and typically contain renewal options. Certain leases contain rent escalation clauses for which Cynosure recognizes the expense on a straight-line basis. Rent expense for the years ended December 31, 2013, 2012 and 2011 was approximately $2.4 million, $2.1 million and $1.8 million, respectively.
	Cynosure leases the buildings portion of its U.S. operating facility and certain equipment and vehicles under capital lease agreements with payments due through May 2027. Commitments under Cynosure’s lease arrangements are as follows, in thousands:
		Operating		Capital
		Leases		Leases
	2014	$	1,330	$	701
	2015		776		115
	2016		889		2,069
	2017		903		2,524
	2018		847		2,516
	Thereafter		2,910		22,677
	Total minimum lease payments	$	7,655	$	30,602
	Less amount representing interest				(15,359	)
	Present value of obligations under capital leases			$	15,243
	Current portion of capital lease obligations				286
	Capital lease obligations, net of current portion			$	14,957

Summary_Selected_Quarterly_Fin

Summary Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary Selected Quarterly Financial Data (Unaudited)	'
	15. Summary Selected Quarterly Financial Data (Unaudited)
	The following table sets forth certain unaudited consolidated quarterly statement of operations data for the eight quarters ended December 31, 2013. This information is unaudited, but in the opinion of management, it has been prepared on the same basis as the audited consolidated financial statements and all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to state fairly the unaudited consolidated quarterly results of operations. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period.
		Quarter Ended
		March 31,		June 30,			Sept. 30,			Dec. 31,
		2013		2013			2013			2013
		(In thousands, except per share data)
	Revenues	$	40,690	$	50,091		$	60,692		$	74,537
	Gross profit	$	23,687	$	27,787		$	34,134		$	44,672
	Income (loss) from operations	$	1,988	$	(14,639	)	$	(1,426	)	$	8,250
	Net income (loss)	$	1,239	$	(8,954	)	$	(1,281	)	$	7,349
	Basic net income (loss) per share	$	0.08	$	(0.54	)	$	(0.06	)	$	0.33
	Diluted net income (loss) per share	$	0.07	$	(0.54	)	$	(0.06	)	$	0.33
		Quarter Ended
		March 31,		June 30,			Sept. 30,			Dec. 31,
		2012		2012			2012			2012
		(In thousands, except per share data)
	Revenues	$	34,168	$	39,573		$	37,083		$	42,669
	Gross profit	$	19,508	$	23,040		$	21,587		$	24,791
	Income from operations	$	858	$	3,693		$	3,343		$	4,239
	Net income	$	819	$	2,680		$	3,423		$	4,039
	Basic net income per share	$	0.07	$	0.21		$	0.26		$	0.28
	Diluted net income per share	$	0.06	$	0.2		$	0.25		$	0.27

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Reclassifications	'
	Reclassifications
	Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation within the consolidated statements of operations.
Management Estimates	'
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures at the date of the financial statements and during the reporting period. Components particularly subject to estimation include the allowance for doubtful accounts, inventory reserves, intangible assets, impairment analysis of goodwill and intangibles, deferred tax assets, liabilities and valuation allowances, fair value of stock options and investments and accrued warranties. On an ongoing basis, management evaluates its estimates. Actual results could differ from these estimates.
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Cynosure, Inc. and its wholly owned subsidiaries: Cynosure GmbH, Cynosure S.A.R.L., Cynosure UK Limited, Cynosure Spain, S.L., Cynosure KK, Suzhou Cynosure Medical Devices, Co., Cynosure Mexico, Cynosure Korea Limited, Cynosure Pty Limited, Palomar Medical Technologies GmbH, Palomar Japan KK, and Cynosure B.V. All significant intercompany balances and transactions have been eliminated.
Cash, Cash Equivalents, Short and Long-Term Marketable Securities	'
	Cash, Cash Equivalents, Short and Long-Term Marketable Securities
	Cynosure considers all short-term, highly liquid investments with original maturities at the time of purchase of 90 days or less to be cash equivalents. Cynosure accounts for short and long-term marketable securities as available-for-sale in accordance with Accounting Standards Codification (ASC) 320, Investments—Debt and Equity Securities Topic. Under ASC 320, securities purchased to be held for indefinite periods of time and not intended at the time of purchase to be held until maturity are classified as available-for-sale securities. ASC 320 requires Cynosure to recognize all marketable securities on the consolidated balance sheets at fair value. Cynosure’s marketable securities are stated at fair value based on quoted market prices. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive loss in shareholders’ equity. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. The cost of securities sold is determined by the specific identification method. Cynosure continually evaluates whether any marketable investments have been impaired and, if so, whether such impairment is temporary or other than temporary.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Cynosure’s financial instruments consist of cash, cash equivalents, short and long-term marketable securities, accounts receivable and capital leases. Cynosure’s estimate of fair value for financial instruments, other than marketable securities, approximates their carrying value at December 31, 2013 and 2012.
	ASC 820, Fair Value Measurement Topic, applies to all financial assets and financial liabilities that are being measured and reported on a fair value basis, establishes a framework for measuring fair value of assets and liabilities and expands disclosures about fair value measurements.
Accounts Receivable and Concentration of Credit Risk	'
	Accounts Receivable and Concentration of Credit Risk
	Cynosure’s accounts receivable balance, net of allowance for doubtful accounts, was $36.6 million as of December 31, 2013, compared with $18.0 million as of December 31, 2012. The allowance for doubtful accounts as of December 31, 2013 and 2012 was $1.8 million and $2.0 million, respectively. Cynosure maintains an allowance for doubtful accounts based upon the aging of its receivable balances, known collectibility issues and Cynosure’s historical experience with losses. Cynosure works to mitigate bad debt exposure through its credit evaluation policies, reasonably short payment terms and geographical dispersion of sales. Cynosure’s revenue includes export sales to foreign companies located principally in Europe, the Asia/Pacific region and the Middle East. Cynosure obtains letters of credit for foreign sales that the Company considers to be at risk.
	No customer accounted for 10% or greater of revenue during 2013, 2012 or 2011. No customer accounted for 10% or greater of accounts receivable as of December 31, 2013 or 2012. Accounts receivable allowance activity consisted of the following for the years ended December 31:
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	2,043		$	1,872		$	2,207
	Additions		1,058			591			167
	Deductions		(1,298	)		(420	)		(502	)
	Balance at end of year	$	1,803		$	2,043		$	1,872
Inventory	'
	Inventory
	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:
		December 31,
		2013			2012
		(In thousands)
	Raw materials	$	17,234		$	9,076
	Work in process		2,316			1,134
	Finished goods		34,548			22,696
		$	54,098		$	32,906
	Included in finished goods are lasers used for demonstration purposes. Cynosure’s policy is to include demonstration lasers as inventory for a period of up to one year after being used by the sales force at which time the demonstration lasers are either sold or transferred to fixed assets at the lower of cost or market and depreciated over their estimated useful life of three years. Similar to any other finished goods in inventory, Cynosure accounts for such demonstration inventory in accordance with the policy for excess and obsolescence review of Cynosure’s entire inventory.
	Cynosure’s excess and obsolescence reserve policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for products and market conditions. Cynosure regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining management’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted in the future. If inventory is determined to be overvalued, Cynosure recognizes such costs as cost of goods sold at the time of such determination. Although Cynosure performs a detailed review of its forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the value of Cynosure’s inventory and reported operating results.
	Cynosure purchases raw material components as well as certain finished goods from sole source suppliers. A delay in the production capabilities of these vendors could cause a delay in Cynosure’s manufacturing, and a possible loss of revenues, which would adversely affect operating results.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Assets under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the respective lease term. Included in property and equipment are certain lasers that are used for demonstration purposes. Maintenance and repairs are charged to expense as incurred. Cynosure continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Cynosure evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Cynosure believes that, as of each of the balance sheet dates presented, none of Cynosure’s long-lived assets were impaired.
Intangible Assets	'
	Intangible Assets
	Cynosure capitalizes and includes in intangible assets the costs of developed technology and patents, customer relationships, trade names and business licenses. Intangible assets are recorded at fair value and stated net of accumulated amortization and impairments. Cynosure amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 5 to 23 years. Cynosure evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, Cynosure estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, Cynosure uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s remaining useful life is changed, Cynosure will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life.
Goodwill	'
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. Cynosure does not amortize its goodwill, but instead tests for impairment at least annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. Cynosure’s annual test for impairment occurs on the first day of its fourth quarter.
	Cynosure has adopted ASU 2011-08 Intangibles—Goodwill and Other, an amendment to ASC 350, which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.
	Cynosure has one reporting unit for goodwill impairment testing and has performed a qualitative assessment on that reporting unit. As a result of this assessment, the Company determined that goodwill is not impaired as of December 31, 2013.
Revenue Recognition and Deferred Revenue	'
	Revenue Recognition and Deferred Revenue
	Cynosure generates revenue from the sale of aesthetic treatment systems that are used by physicians and other practitioners to perform various non-invasive and minimally invasive aesthetic procedures. These systems incorporate a broad range of laser and other light-based energy sources. Cynosure offers service and warranty contracts in connection with these sales.
	Cynosure recognizes revenue from sales of aesthetic treatment systems and parts and accessories in accordance with the Revenue Recognition Topic ASC 605-10-S99. Cynosure recognizes revenue from sales of its treatment systems and parts and accessories upon delivery, provided there are no uncertainties regarding customer acceptance, there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectibility of the related receivable is reasonably assured. Revenues from the sales of service and warranty contracts are deferred and recognized on a straight-line basis over the contract period as services are provided. Payments received by Cynosure in advance of product delivery or performance of services are deferred until earned.
	Cynosure recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, Cynosure recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by Cynosure’s licensees occurred. Royalty revenues also include amounts due from settlements with licensees for back-owed royalties from prior periods. These settlement amounts are considered revenue, when collectability is reasonably assured, because they constitute Cynosure’s ongoing major or central operations.
	In December 2013, Cynosure completed a comprehensive settlement agreement with Tria Beauty, Inc. (“Tria”) which ended the patent infringement litigation between Tria and Palomar Medical Technologies, Inc. (“Palomar”). Under the agreement, Cynosure is entitled to receive $10.0 million plus future royalty payments. Cynosure will pay approximately $2.0 million of this revenue to Massachusetts General Hospital (“MGH”) under an exclusive license agreement between Palomar and MGH, which will be recorded as cost of revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $4.0 million of this revenue in the year ended December 31, 2013, which is recorded as royalty revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $1.0 million in cost of revenues in the year ended December 31, 2013 for legal and license fees related to this settlement.
	Multiple-element arrangements are evaluated in accordance with the principles of Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition Topic—Multiple Element Arrangements and Cynosure allocates revenue among the elements based upon each element’s relative fair value.
	In accordance with the provisions of ASC 605-45, Revenue Recognitions Topic—Principal Agent Considerations, Cynosure records shipping and handling costs billed to its customers as a component of revenue, and the underlying expense as a component of cost of revenue. Shipping and handling costs included as a component of revenue totaled approximately $0.6 million, $0.4 million, and $0.4 million for the years ended December 31, 2013, 2012 and 2011, respectively. Shipping and handling costs included as a component of cost of revenue totaled $0.6 million, $0.5 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Cynosure collects sales tax from its customers on product sales for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Cynosure presents its sales taxes on a net basis; therefore, these taxes are excluded from revenues.
	In 2013, most of the products and systems that Cynosure sells became subject to a new excise tax on sales of certain medical devices in the United States by the manufacturer, producer or importer in an amount equal to 2.3% of the sale price. These taxes are included within revenue and cost of revenues in Cynosure’s consolidated statement of operations.
Cost of Revenues	'
	Cost of Revenues
	Cynosure’s cost of revenues consist primarily of material, labor and manufacturing overhead expenses and includes the cost of components and subassemblies supplied by third party suppliers. Cost of revenues also includes royalties incurred on certain products sold by Cynosure and its licensees, costs incurred in connection with Cynosure’s efforts to litigate or settle additional third party license agreements, service and warranty expenses, as well as salaries and personnel-related expenses, including stock-based compensation, for Cynosure’s operations management team, purchasing and quality control.
Product Warranty Costs	'
	Product Warranty Costs
	Cynosure typically provides a one-year parts and labor warranty on end-user sales of lasers. Distributor sales generally include a one-year warranty on parts only. Estimated future costs for initial product warranties are provided for at the time of revenue recognition. The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:
		Years Ended December 31,
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	3,415		$	3,171		$	2,112
	Warranty provision related to new sales		9,114			4,641			4,729
	Warranty provision assumed from acquisitions		1,422			—			342
	Costs incurred		(7,300	)		(4,397	)		(4,012	)
	Balance at end of year	$	6,651		$	3,415		$	3,171
Research and Development	'
	Research and Development
	Research and development costs consist of salaries and other personnel-related expenses, including stock-based compensation, of employees primarily engaged in research, development and engineering activities and materials used and other overhead expenses incurred in connection with the design and development of Cynosure’s products and from time to time expenses associated with collaborative research agreements that the Company may enter into. These costs are expensed as incurred.
	In June 2009, Cynosure entered into a cooperative development agreement (“Agreement”) with Unilever Ltd. (“Unilever”) to develop and commercialize light-based devices for the emerging home use personal care market. Under the terms of this Agreement, Cynosure performs certain research and development activities to assist in the advancement of the commercialization of these devices, the cost of which is partially funded by Unilever. Cynosure incurred $0.5 million, $0.9 million, and $1.8 million of research and development costs in connection with this Agreement during fiscal 2013, 2012 and 2011, respectively, and recorded $0 million, $0.5 million, and $1.7 million of reimbursements from Unilever as a reduction to research and development expenses in the respective fiscal periods. In July 2012, Cynosure received FDA clearance in the United States to market the product in the United States. Unilever expects to launch the product commercially in the first half of 2014. Once the product is commercialized, Cynosure will be entitled to future royalty payments from Unilever.
Advertising Costs	'
	Advertising Costs
	Cynosure expenses advertising costs as incurred. Advertising costs totaled $1.1 million, $0.6 million and $0.5 million for the years ended December 31, 2013, 2012 and 2011, respectively.
Foreign Currency Translation	'
	Foreign Currency Translation
	The financial statements of Cynosure’s foreign subsidiaries are translated from local currency into U.S. dollars using the current exchange rate at the balance sheet date for assets and liabilities, and the average exchange rate prevailing during the period for revenue and expenses. The functional currency for Cynosure’s foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Certain intercompany and third party foreign currency-denominated transactions generated foreign currency remeasurement gains (losses) of approximately $334,000, $360,000 and $(318,000) during 2013, 2012 and 2011, respectively, which are included in other income (expense), net, in the consolidated statements of operations.
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss
	Changes to accumulated other comprehensive loss during the year ended December 31, 2013 were as follows (in thousands):
		Unrealized			Translation			Accumulated
		Gain on			Adjustment			Other
		Marketable						Comprehensive
		Securities, net						Loss
		of taxes
	Balance—December 31, 2012	$	13		$	(1,612	)	$	(1,599	)
	Current period other comprehensive gain		23			77			100
	Balance—December 31, 2013	$	36		$	(1,535	)	$	(1,499	)
Stock-Based Compensation	'
	Stock-Based Compensation
	Cynosure follows the fair value recognition provisions of ASC 718, Stock Compensation Topic (ASC 718). Cynosure expenses the fair value of stock options over the service period. ASC 718 requires companies to utilize an estimated forfeiture rate when calculating the expense for the period. Accordingly, Cynosure reviews its actual forfeiture rates and periodically aligns its stock compensation expense with the options that are vesting.
	Cynosure recorded stock-based compensation expense of $3.7 million, $2.9 million and $2.6 million for the years ended December 31, 2013, 2012 and 2011, respectively. As of December 31, 2013 and 2012, respectively, Cynosure had $23,000 and $18,000 of stock-based compensation expense capitalized as a part of inventory.
	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective options, as follows:
		Years Ended December 31,
		2013			2012			2011
		(In thousands)
	Cost of revenues	$	174		$	127		$	134
	Sales and marketing		1,090			857			829
	Research and development		594			495			446
	General and administrative		1,830			1,431			1,152
	Total stock-based compensation expense	$	3,688		$	2,910		$	2,561
	As of December 31, 2013, there was $6.7 million of unrecognized compensation expense related to non-vested share awards that is expected to be recognized on a straight-line basis over a weighted average period of 1.37 years. Cash received from option exercises was $2.7 million, $7.2 million and $0.2 million during the years ended December 31, 2013, 2012 and 2011, respectively.
	Cynosure granted 617,510, 405,790 and 411,104 stock options during the years ended December 31, 2013, 2012 and 2011, respectively. Cynosure uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair value of the options granted during the years ended December 31, 2013, 2012 and 2011 was $10.25, $9.23 and $7.26, respectively, using the following assumptions:
		Years Ended December 31,
		2013		2012	2011
	Risk-free interest rate	0.33% - 1.49%		0.61% - 0.86%	0.87% - 2.37%
	Expected dividend yield	—		—	—
	Expected term	2 years - 4.8 years		5.8 years	5.8 years
	Expected volatility	44% - 56%		56% - 57%	55% - 57%
	Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Cynosure’s estimated expected stock price volatility is based on its own historical volatility for the 2013, 2012 and 2011 periods. Cynosure’s expected term of options granted during the year ended December 31, 2013 represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and Cynosure’s historical exercise patterns. Cynosure’s expected term of options granted during the years ended December 31, 2012 and 2011 was derived from the simplified method described in ASC 718-10-S99. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield of zero is based on the fact that Cynosure has never paid cash dividends and has no present intention to pay cash dividends.
Interest (Expense) Income, Net	'
	Interest (Expense) Income, net
	Interest (expense) income consists primarily of interest charges on capital lease obligations, and interest earned on Cynosure’s short and long-term marketable securities consisting of state and municipal bonds, U.S. government agencies and treasuries, corporate obligations and commercial paper. Cynosure expects interest expense to increase in 2014 as a result of interest charges incurred on the buildings portion of its U.S. operating facility.
Income Taxes	'
	Income Taxes
	Cynosure provides for income taxes in accordance with ASC 740, Accounting for Income Taxes (ASC 740). ASC 740 recognizes tax assets and liabilities for the cumulative effect of all temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities, and are measured using the enacted tax rates that will be in effect when these differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	Cynosure accounts for uncertain tax positions following the provisions of ASC 740. ASC 740 clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Net (Loss) Income Per Common Share	'
	Net (Loss) Income per Common Share
	Basic net (loss) income per share is determined by dividing net (loss) income by the weighted average common shares outstanding during the period. Diluted net (loss) income per share is determined by dividing net (loss) income by the diluted weighted average shares outstanding during the period. Diluted weighted average shares reflect the dilutive effect, if any, of common stock options based on the treasury stock method. For the year ended December 31, 2013 and 2012, there are no outstanding Class B shares, and Cynosure may not issue Class B shares in the future. For the years ended December 31, 2011, common shares outstanding include both Class A and Class B as each share participated equally in earnings. Class B shares were convertible at any time into shares of Class A on a one-for-one basis at the option of the holder.
	The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011 is as follows (in thousands, except per share data):
		Years Ended December 31,
		2013			2012			2011
	Net (loss) income	$	(1,647	)	$	10,961		$	(2,905	)
	Basic weighted average common shares outstanding		19,325			13,189			12,585
	Weighted average common stock equivalents		—			603			—
	Diluted weighted average common shares outstanding		19,325			13,792			12,585
	Basic net (loss) income per share	$	(0.09	)	$	0.83		$	(0.23	)
	Diluted net (loss) income per share	$	(0.09	)	$	0.79		$	(0.23	)
	For the year ended December 31, 2013, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2013, outstanding options to purchase 1.3 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
	For the year ended December 31, 2012, options to purchase approximately 0.7 million shares of Cynosure’s Class A common stock were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.
	For the year ended December 31, 2011, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2011, outstanding options to purchase 2.0 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. Under this ASU, an entity is required to provide information about the amounts reclassified out of Accumulated Other Comprehensive Income (AOCI) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. ASU 2013-02 is effective for interim and annual periods beginning after December 15, 2012. The adoption of this guidance did not materially impact Cynosure’s financial statements or disclosures.
Lease Commitments	'
	ASC 840, Leases, establishes the framework for accounting for the Amendment. In accordance with ASC 840, Cynosure is accounting for the land portion of the leased premises as an operating lease. The buildings at 5 Carlisle Road and 3 Carlisle Road have met the criteria for capital lease accounting under ASC 840-10-25-1, and thus Cynosure is accounting for the buildings portion of the leased premises as capital leases and incurring interest charges accordingly. The interest rates used for the 5 Carlisle Road and 3 Carlisle Road capital leases are 10.8% and 8.8%, respectively. The expansion of the leased premises, as well as improvements to the leased premises, are recorded on the balance sheet as leasehold improvements within property, plant and equipment. Assets under capital leases and leasehold improvements related to the Amendment are amortized using the straight-line method over the respective lease term.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Accounts Receivable Allowance Activity	'
	Accounts receivable allowance activity consisted of the following for the years ended December 31:
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	2,043		$	1,872		$	2,207
	Additions		1,058			591			167
	Deductions		(1,298	)		(420	)		(502	)
	Balance at end of year	$	1,803		$	2,043		$	1,872
Inventories	'
	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:
		December 31,
		2013			2012
		(In thousands)
	Raw materials	$	17,234		$	9,076
	Work in process		2,316			1,134
	Finished goods		34,548			22,696
		$	54,098		$	32,906
Activity in the Accrued Warranty Account	'
	The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:
		Years Ended December 31,
		2013			2012			2011
		(In thousands)
	Balance at beginning of year	$	3,415		$	3,171		$	2,112
	Warranty provision related to new sales		9,114			4,641			4,729
	Warranty provision assumed from acquisitions		1,422			—			342
	Costs incurred		(7,300	)		(4,397	)		(4,012	)
	Balance at end of year	$	6,651		$	3,415		$	3,171
Changes to Accumulated Other Comprehensive Loss	'
	Changes to accumulated other comprehensive loss during the year ended December 31, 2013 were as follows (in thousands):
		Unrealized			Translation			Accumulated
		Gain on			Adjustment			Other
		Marketable						Comprehensive
		Securities, net						Loss
		of taxes
	Balance—December 31, 2012	$	13		$	(1,612	)	$	(1,599	)
	Current period other comprehensive gain		23			77			100
	Balance—December 31, 2013	$	36		$	(1,535	)	$	(1,499	)
Summary of Stock-Based Compensation Expenses	'
	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective options, as follows:
		Years Ended December 31,
		2013			2012			2011
		(In thousands)
	Cost of revenues	$	174		$	127		$	134
	Sales and marketing		1,090			857			829
	Research and development		594			495			446
	General and administrative		1,830			1,431			1,152
	Total stock-based compensation expense	$	3,688		$	2,910		$	2,561
Summary of Share-Based compensation Arrangement Fair Value Assumptions	'
	The weighted average fair value of the options granted during the years ended December 31, 2013, 2012 and 2011 was $10.25, $9.23 and $7.26, respectively, using the following assumptions:
		Years Ended December 31,
		2013		2012	2011
	Risk-free interest rate	0.33% - 1.49%		0.61% - 0.86%	0.87% - 2.37%
	Expected dividend yield	—		—	—
	Expected term	2 years - 4.8 years		5.8 years	5.8 years
	Expected volatility	44% - 56%		56% - 57%	55% - 57%
Schedule of Reconciliation of Basic and Diluted Shares	'
	The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2013, 2012 and 2011 is as follows (in thousands, except per share data):
		Years Ended December 31,
		2013			2012			2011
	Net (loss) income	$	(1,647	)	$	10,961		$	(2,905	)
	Basic weighted average common shares outstanding		19,325			13,189			12,585
	Weighted average common stock equivalents		—			603			—
	Diluted weighted average common shares outstanding		19,325			13,792			12,585
	Basic net (loss) income per share	$	(0.09	)	$	0.83		$	(0.23	)
	Diluted net (loss) income per share	$	(0.09	)	$	0.79		$	(0.23	)

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Measurement of Fair Value Hierarchy for Financial Assets	'
	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2013 (in thousands):
			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	5,185	$	—	$	—	$	5,185
	State and municipal bonds(2)		$	—		18,133	$	—		18,133
	Treasuries and government agencies			—		15,028		—		15,028
	Corporate obligations and commercial paper			—		3,020		—		3,020
	Equity securities			49		—		—		49
	Total		$	5,234	$	36,181	$	—	$	41,415
	-1	Included in cash and cash equivalents at December 31, 2013.
	-2	$0.8 million included in cash and cash equivalents at December 31, 2013.

Short_and_LongTerm_Marketable_1

Short and Long-Term Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Schedule of Marketable Securities	'
	As of December 31, 2013, Cynosure’s marketable securities consist of the following (in thousands):
		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-Sale Securities:
	Cash equivalents:
	State and municipal bonds	$	793	$	793	$	—	$	—
	Total cash equivalents	$	793	$	793	$	—	$	—
	Short-term marketable securities:
	State and municipal bonds	$	10,552	$	10,551	$	1	$	—
	Treasuries and government agencies		15,028		15,018		10		—
	Corporate obligations and commercial paper		1,004		1,004		—		—
	Equity securities		49		8		41		—
	Total short-term marketable securities	$	26,633	$	26,581	$	52	$	—
	Long-term marketable securities:
	State and municipal bonds	$	6,788	$	6,787	$	1	$	—
	Corporate obligations and commercial paper		2,016		2,015		1		—
	Total long-term marketable securities	$	8,804	$	8,802	$	2	$	—
	Total available-for-sale securities	$	36,230	$	36,176	$	54	$	—
	Total marketable securities	$	35,437
	As of December 31, 2012, Cynosure’s marketable securities consist of the following (in thousands):
		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-sale Securities:
	Cash equivalents:
	State and municipal bonds	$	4,417	$	4,417	$	—	$	—
	Government agencies	$	1,000	$	1,000	$	—	$	—
	Total cash equivalents	$	5,417	$	5,417	$	—	$	—
	Short-term marketable securities:
	State and municipal bonds	$	33,250	$	33,251	$	6	$	(7	)
	Treasuries and government agencies		7,346		7,345		1		—
	Equity securities		21		6		15		—
	Total short-term marketable securities	$	40,617	$	40,602	$	22	$	(7	)
	Long-term marketable securities:
	State and municipal bonds	$	18,046	$	18,052	$	2	$	(8	)
	Treasuries and government agencies		2,025		2,021		4		—
	Total long-term marketable securities	$	20,071	$	20,073	$	6	$	(8	)
	Total available-for-sale securities	$	66,105	$	66,092	$	28	$	(15	)
	Total marketable securities	$	60,688
Schedule of Available-for-Sale Debt Securities Mature	'
	As of December 31, 2013, Cynosure’s available-for-sale debt securities mature as follows (in thousands):
				Maturities
		Total		Less Than One Year		One to Five Years		More than five years
	State and municipal bonds	$	18,133	$	11,345	$	6,788	$	—
	Treasuries and government agencies		15,028		15,028		—		—
	Corporate obligations and commercial paper		3,020		1,004		2,016		—
	Total available-for-sale debt securities	$	36,181	$	27,377	$	8,804	$	—

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Estimated Fair Value of Net Assets Acquired	'
	The following table summarizes the purchase price allocation, net of $117.9 million in cash, cash equivalents and marketable securities acquired (in thousands):
	Purchase price:
	Cash and stock paid	$	287,204
	Cash, cash equivalents and marketable securities acquired		(117,929	)
	Purchase price, net	$	169,275
	Assets (liabilities) acquired:
	Accounts receivable		11,761
	Inventory		20,054
	Prepaids and other assets		722
	Property and equipment		30,639
	Other assets		132
	Intangible assets		52,340
	Goodwill		79,345
	Accounts payable		(7,269	)
	Accrued expenses		(9,771	)
	Deferred revenue		(3,528	)
	Deferred tax liability		(5,150	)
	Total	$	169,275
Pro-forma Condensed Consolidated Operating Results	'
	The following unaudited pro forma condensed consolidated operating results for the years ended December 31, 2013 and 2012 summarize the combined results of operations for Cynosure and Palomar.
		Year Ended
		December 31,
		2013			2012
	Revenue (unaudited, in thousands)	$	267,941		$	231,153
	Pre-tax income (loss) (unaudited, in thousands)	$	12,452		$	(42,199	)

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Changes to Goodwill	'
	Changes to goodwill during the year ended December 31, 2013 were as follows (in thousands):
	Balance—December 31, 2012	$	15,811
	Palomar acquisition		79,345
	Translation adjustment		27
	Balance—December 31, 2013	$	95,183
Schedule of Components of Other Intangible Assets	'
	Other intangible assets consist of the following at December 31, 2013 and December 31, 2012 (in thousands):
		Developed			Business			Customer			Trade			Other			Total
		Technology			Licenses			Relationships			Names
		& Patents
	December 31, 2013
	Cost	$	27,510		$	384		$	15,833		$	16,930		$	1,338		$	61,995
	Translation adjustment		—			40			26			—			4			70
	Accumulated amortization		(2,216	)		(239	)		(3,662	)		(761	)		(8	)		(6,886	)
	Balance, December 31, 2013	$	25,294		$	185		$	12,197		$	16,169		$	1,334		$	55,179
	December 31, 2012
	Cost	$	3,250		$	384		$	3,323		$	2,650		$	48		$	9,655
	Translation adjustment		—			38			24			—			3			65
	Accumulated amortization		(1,292	)		(195	)		(2,019	)		(272	)		(5	)		(3,783	)
	Balance, December 31, 2012	$	1,958		$	227		$	1,328		$	2,378		$	46		$	5,937
Schedule of Amortization Expenses on Intangible Assets	'
	As of December 31, 2013, amortization expense on existing intangible assets for the next five years and beyond is as follows (table in thousands):
	2014	$	8,375
	2015		8,397
	2016		7,616
	2017		5,677
	2018		4,222
	2019 and Thereafter		19,561
	Total	$	53,848

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Total Revenue by Geographic Destination	'
	The following table represents total revenue by geographic destination:
		Year Ended December 31,
		2013			2012			2011
		(In thousands)
	United States	$	111,179		$	72,704		$	43,903
	Europe		39,529			28,808			27,918
	Asia/Pacific		52,574			39,991			27,357
	Other		22,728			11,990			11,424
		$	226,010		$	153,493		$	110,602
Schedule of Total Assets by Geographic Area	'
	Total assets by geographic area are as follows:
		December 31,
		2013			2012
		(In thousands)
	United States	$	390,941		$	210,596
	Europe		15,916			15,623
	Asia/Pacific		11,496			11,038
	Eliminations		(3,859	)		(2,688	)
		$	414,494		$	234,569
Schedule of Long-Lived Assets by Geographic Area	'
	Long-lived assets by geographic area are as follows:
		December 31,
		2013			2012
		(In thousands)
	United States	$	24,120		$	7,266
	Europe		2,403			1,570
	Asia/Pacific		1,600			432
		$	28,123		$	9,268

Balance_Sheet_Accounts_Tables

Balance Sheet Accounts (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Property and Equipment	'
	Property and equipment consists of the following at December 31:
		Estimated		2013			2012
		Useful		Cost			Cost
		Life
		(Years)
		(In thousands)
	Equipment		5-Mar	$	7,835		$	5,098
	Furniture and fixtures		5-Mar		2,698			1,982
	Computer equipment and software		3		5,047			3,796
	Leased Equipment		4-Mar		1,660			1,774
	Leased Buildings		14		13,327			—
	Leasehold improvements		5		2,898			2,504
	Demonstration equipment		3		24,094			20,095
	Construction in-progress				495			571
					58,054			35,820
	Less: Accumulated depreciation and amortization				(31,609	)		(27,613	)
				$	26,445		$	8,207
Accrued Expenses	'
	Accrued expenses consist of the following at December 31:
		2013		2012
		(In thousands)
	Accrued payroll and taxes	$	9,547	$	3,039
	Accrued employee benefits		2,093		1,149
	Accrued warranty costs		6,651		3,415
	Accrued commissions		5,243		2,620
	Accrued other		13,443		6,978
		$	36,977	$	17,201
Other Noncurrent Liabilities	'
	Other noncurrent liabilities consist of the following at December 31:
		2013		2012
		(In thousands)
	Noncurrent deferred rent	$	2	$	1,473
	Noncurrent deferred tax liability		8,512		473
	Noncurrent income tax reserve		51		319
		$	8,565	$	2,265

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Option Activity	'
	Stock option activity under the 2004 Plan and the 2005 Plan is as follows:
		Number of			Exercise Price		Weighted-		Weighted-		Aggregate
		Options			Range		Average		Average		Intrinsic
							Exercise		Remaining		Value
							Price		Contractual		(in thousands)
									Life
	Vested		1,424,788			3.00 - 36.94		16.2				11,890
	Unvested		527,823			9.56 - 24.99		16.15				4,224
	Outstanding, December 31, 2012		1,952,611		$	3.00 - $36.94	$	16.18		6.49 years	$	16,114
	Granted		617,510			22.12 - 28.68		25.73				1,184
	Exercised		(202,603	)		3.00 - 21.73		13.43				2,345
	Forfeited		(63,652	)		6.78 - 36.94		22.63				293
	Outstanding, December 31, 2013		2,303,866		$	3.00 - $36.94	$	18.81		6.51 years	$	19,046
	Vested		1,596,565			3.00 - 36.94		16.93		5.35 years		16,061
	Unvested		707,301			9.56 - 28.68		23.06		9.13 years		2,985
	Vested or expected to vest, December 31, 2013		2,285,851		$	3.00 - $36.94	$	18.75		6.49 years	$	19,008
	Exercisable, December 31, 2013		1,596,565		$	3.00 - $36.94	$	16.93		5.35 years	$	16,061

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
(Loss) Income before Income Tax (Benefit) Provision	'
	(Loss) income before income tax (benefit) provision consists of the following:
		2013			2012			2011
		(In thousands)
	Domestic	$	(8,633	)	$	10,344		$	(2,710	)
	Foreign		3,096			2,381			612
	Total	$	(5,537	)	$	12,725		$	(2,098	)
(Benefit) Provision for Income Taxes	'
	The (benefit) provision for income taxes consists of:
		2013			2012			2011
		(In thousands)
	Current:
	Federal	$	732		$	1,382		$	241
	State		214			128			179
	Foreign		890			606			433
	Total current		1,836			2,116			853
	Deferred:
	Federal		(5,406	)		152			—
	State		(304	)		—			—
	Foreign		(16	)		(504	)		(46	)
	Total deferred		(5,726	)		(352	)		(46	)
		$	(3,890	)	$	1,764		$	807
Reconciliation of Federal Statutory Rate	'
	A reconciliation of the federal statutory rate to Cynosure’s effective tax rate is as follows for the years ended December 31:
		2013			2012			2011
	Income tax provision at federal statutory rate:		35	%		35	%		35	%
	Increase (decrease) in tax resulting from -
	State taxes, net of federal benefit		(3.1	)		0.7			(8.9	)
	Nondeductible expenses		(11.9	)		2.1			(12.1	)
	Tax-exempt interest income		0.5			(0.3	)		1.4
	Effect of foreign taxes		2.7			(1.8	)		3.6
	Stock-based compensation		(0.1	)		(0.9	)		(0.6	)
	Research and development credit		25.8			—			23.9
	Change in uncertain tax positions		4.8			2.5			—
	Change in valuation allowance		162			(20.5	)		(81.5	)
	Change in control payments		(128.8	)		—			—
	Transaction costs		(13.6	)		—			—
	Other		(3.1	)		(2.9	)		0.7
	Effective income tax rate		70.2	%		13.9	%		(38.5	)%
Significant Components of Deferred Tax Assets and Liabilities	'
	Significant components of Cynosure’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		2013			2012
		(In thousands)
	Deferred tax assets:
	Accrued expenses and reserves	$	9,747		$	2,741
	Domestic net operating loss & tax credit carry-forwards		19,925			1,692
	Foreign net operating loss carry-forwards		2,022			682
	Stock-based compensation		6,020			5,620
	Capital leases		5,472			—
	Intangible assets		—			520
	Other deferred tax assets		1,636			1,854
	Gross deferred tax assets	$	44,822		$	13,109
	Valuation allowance		(19,186	)		(11,804	)
	Total deferred tax assets (after valuation allowance)	$	25,636		$	1,305
	Long-term deferred tax liabilities:
	Intangible assets	$	(18,227	)	$	—
	Fixed assets		(5,463	)		(387	)
	Other deferred tax liabilities		(534	)		—
	Total long-term deferred tax liabilities	$	(24,224	)	$	(387	)
	Net deferred tax assets	$	1,412		$	918
Changes in Gross Unrecognized Tax Benefits	'
	The aggregate changes in gross unrecognized tax benefits during the years ended December 31, 2013, 2012 and 2011 were as follows (in thousands):
		2013			2012			2011
	Balance at beginning of year	$	586		$	—		$	—
	Increases for tax positions taken during current period		76			398			—
	Increases for tax positions taken in prior periods		—			188			—
	Increases for acquired tax positions taken in prior periods		1,625			—			—
	Decreases for tax positions taken in prior periods		(398	)		—			—
	Decreases for lapse in statutes		(188	)		—			—
	Balance at end of year	$	1,701		$	586		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Operating Facility, Certain Equipment and Vehicles Under Operating Lease and Capital Lease Agreements with Payments	'
	Cynosure leases the buildings portion of its U.S. operating facility and certain equipment and vehicles under capital lease agreements with payments due through May 2027. Commitments under Cynosure’s lease arrangements are as follows, in thousands:
		Operating		Capital
		Leases		Leases
	2014	$	1,330	$	701
	2015		776		115
	2016		889		2,069
	2017		903		2,524
	2018		847		2,516
	Thereafter		2,910		22,677
	Total minimum lease payments	$	7,655	$	30,602
	Less amount representing interest				(15,359	)
	Present value of obligations under capital leases			$	15,243
	Current portion of capital lease obligations				286
	Capital lease obligations, net of current portion			$	14,957

Summary_Selected_Quarterly_Fin1

Summary Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Unaudited Consolidated Quarterly Results of Operations	'
	The results of operations for any quarter are not necessarily indicative of the results of operations for any future period.
		Quarter Ended
		March 31,		June 30,			Sept. 30,			Dec. 31,
		2013		2013			2013			2013
		(In thousands, except per share data)
	Revenues	$	40,690	$	50,091		$	60,692		$	74,537
	Gross profit	$	23,687	$	27,787		$	34,134		$	44,672
	Income (loss) from operations	$	1,988	$	(14,639	)	$	(1,426	)	$	8,250
	Net income (loss)	$	1,239	$	(8,954	)	$	(1,281	)	$	7,349
	Basic net income (loss) per share	$	0.08	$	(0.54	)	$	(0.06	)	$	0.33
	Diluted net income (loss) per share	$	0.07	$	(0.54	)	$	(0.06	)	$	0.33
		Quarter Ended
		March 31,		June 30,			Sept. 30,			Dec. 31,
		2012		2012			2012			2012
		(In thousands, except per share data)
	Revenues	$	34,168	$	39,573		$	37,083		$	42,669
	Gross profit	$	19,508	$	23,040		$	21,587		$	24,791
	Income from operations	$	858	$	3,693		$	3,343		$	4,239
	Net income	$	819	$	2,680		$	3,423		$	4,039
	Basic net income per share	$	0.07	$	0.21		$	0.26		$	0.28
	Diluted net income per share	$	0.06	$	0.2		$	0.25		$	0.27

Nature_of_the_Business_Additio

Nature of the Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Country
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Number of countries using international distributors	120
Date of incorporation	10-Jul-91

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Customer	Customer	Customer
	Reporting_Unit
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Liquid investments with original maturities	'90 days	'	'
Accounts receivable balance	$36,587,000	$17,970,000	'
Allowance for doubtful accounts	1,803,000	2,043,000	'
Number of major customer revenue	0	0	0
Number of major customer accounts receivable	0	0	'
Laser transferred to fixed assets useful life	'3 years	'	'
Long lived assets impairment	0	'	'
Goodwill impairment	0	'	'
Number of reporting unit	1	'	'
Shipping and handling billing earned	600,000	400,000	400,000
Shipping and handling cost	600,000	500,000	500,000
Percentage of new excise tax on sale price applicable under condition	2.30%	'	'
Standard product warranty period	'1 year	'	'
Research and development incurred cost	500,000	900,000	1,800,000
Research and development reimbursement	0	500,000	1,700,000
Advertising costs	1,100,000	600,000	500,000
Foreign currency remeasurement (losses) gain	334,000	360,000	-318,000
Stock-based compensation	3,688,000	2,910,000	2,561,000
Stock based compensation expense capitalized to inventory	23,000	18,000	'
Unrecognized compensation expense related to non-vested share awards	6,700,000	'	'
Share based compensation weighted average period	'1 year 4 months 13 days	'	'
Cash received from option exercises	2,700,000	7,200,000	200,000
Stock options granted	617,510	405,790	411,104
Weighted average fair value of the options granted	$10.25	$9.23	$7.26
Cash dividend yield	0.00%	'	'
Common stock conversion basis	'	'	'Class B shares were convertible at any time into shares of Class A on a one-for-one basis at the option of the holder
Common stock conversion ratio	'	'	1
Stock option excluded from computation of earning per share	1,300,000	700,000	2,000,000
Settlement Agreement [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Amount to be received	10,000,000	'	'
Amount to be paid	2,000,000	'	'
Royalty revenue	4,000,000	'	'
Cost of royalty revenue	$1,000,000	'	'
Common Stock Class B [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Common stock conversion ratio	'	1	'
Common Stock, shares outstanding	0	0	'
Maximum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Laser held as inventory period	'1 year	'	'
Intangible assets Amortization over the estimated useful lives	'23 years	'	'
Minimum [Member]	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Intangible assets Amortization over the estimated useful lives	'5 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Accounts Receivable Allowance Activity (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Balance at beginning of year	$2,043	$1,872	$2,207
Additions	1,058	591	167
Deductions	-1,298	-420	-502
Balance at end of year	$1,803	$2,043	$1,872

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounting Policies [Abstract]	'	'
Raw materials	$17,234	$9,076
Work in process	2,316	1,134
Finished goods	34,548	22,696
Inventories, Total	$54,098	$32,906

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Activity in the Accrued Warranty Account (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Balance at beginning of year	$3,415	$3,171	$2,112
Warranty provision related to new sales	9,114	4,641	4,729
Warranty provision assumed from acquisitions	1,422	'	342
Costs incurred	-7,300	-4,397	-4,012
Balance at end of year	$6,651	$3,415	$3,171

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Changes to Accumulated Other Comprehensive Loss (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Unrealized Gain on Marketable Securities, net of taxes, Beginning Balance	$13	'	'
Unrealized Gain on Marketable Securities, net of taxes, Current period other comprehensive gain	23	-10	-6
Unrealized Gain on Marketable Securities, net of taxes, Ending Balance	36	13	'
Translation Adjustment, Beginning Balance	-1,612	'	'
Translation Adjustment, Current period other comprehensive gain	77	452	-97
Translation Adjustment, Ending Balance	-1,535	-1,612	'
Accumulated Other Comprehensive Loss, Beginning Balance	-1,599	'	'
Accumulated Other Comprehensive Loss, Current period other comprehensive gain	100	442	-103
Accumulated Other Comprehensive Loss, Ending Balance	($1,499)	($1,599)	'

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Expenses (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total stock-based compensation expense	$3,688	$2,910	$2,561
Cost of Revenues [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total stock-based compensation expense	174	127	134
Sales and Marketing [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total stock-based compensation expense	1,090	857	829
Research and Development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total stock-based compensation expense	594	495	446
General and Administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total stock-based compensation expense	$1,830	$1,431	$1,152

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Summary of Share-Based Compensation Arrangement Fair Value Assumptions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'	'
Risk-free interest rate Minimum	0.33%	0.61%	0.87%
Risk-free interest rate Maximum	1.49%	0.86%	2.37%
Expected dividend yield	'	'	'
Expected term	'	'5 years 9 months 18 days	'5 years 9 months 18 days
Expected volatility Minimum	44.00%	56.00%	55.00%
Expected volatility Maximum	56.00%	57.00%	57.00%
Minimum [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'	'
Expected term	'2 years	'	'
Maximum [Member]	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'	'
Expected term	'4 years 9 months 18 days	'	'

Recovered_Sheet1

Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Shares (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net (loss) income	$7,349	($1,281)	($8,954)	$1,239	$4,039	$3,423	$2,680	$819	($1,647)	$10,961	($2,905)
Basic weighted average common shares outstanding	'	'	'	'	'	'	'	'	19,325	13,189	12,585
Weighted average common stock equivalents	'	'	'	'	'	'	'	'	'	603	'
Diluted weighted average common shares outstanding	'	'	'	'	'	'	'	'	19,325	13,792	12,585
Basic net (loss) income per share	$0.33	($0.06)	($0.54)	$0.08	$0.28	$0.26	$0.21	$0.07	($0.09)	$0.83	($0.23)
Diluted net (loss) income per share	$0.33	($0.06)	($0.54)	$0.07	$0.27	$0.25	$0.20	$0.06	($0.09)	$0.79	($0.23)

Fair_Value_Measurement_of_Fair

Fair Value - Measurement of Fair Value Hierarchy for Financial Assets (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	$41,415
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	5,234
Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	36,181
Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'
State and Municipal Bonds [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	18,133
State and Municipal Bonds [Member] | Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	18,133
State and Municipal Bonds [Member] | Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'
Treasuries and Government Agencies [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	15,028
Treasuries and Government Agencies [Member] | Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	15,028
Treasuries and Government Agencies [Member] | Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'
Money Market Funds [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	5,185
Money Market Funds [Member] | Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	5,185
Money Market Funds [Member] | Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'
Corporate Obligations and Commercial Paper [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	3,020
Corporate Obligations and Commercial Paper [Member] | Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	3,020
Corporate Obligations and Commercial Paper [Member] | Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'
Equity Securities [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	49
Equity Securities [Member] | Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	49
Equity Securities [Member] | Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of financial assets	'

Fair_Value_Measurement_of_Fair1

Fair Value - Measurement of Fair Value Hierarchy for Financial Assets (Parenthetical) (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	$41,415
State and Municipal Bonds [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	18,133
Cash and Cash Equivalents [Member] | State and Municipal Bonds [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	$800

Short_and_LongTerm_Marketable_2

Short and Long-Term Marketable Securities - Additional Information (Detail) (USD $)	Dec. 31, 2013
Investments Debt And Equity Securities [Abstract]	'
Available for sale securities in debt	$36,200,000
Available for sale securities in equity	$49,000

Short_and_LongTerm_Marketable_3

Short and Long-Term Marketable Securities - Schedule of Marketable Securities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	$36,230	$66,105
Amortized Cost	36,176	66,092
Unrealized Gains	54	28
Unrealized Losses	'	-15
Total marketable securities	35,437	60,688
Cash Equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	793	5,417
Amortized Cost	793	5,417
Cash Equivalents [Member] | State and Municipal Bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	793	4,417
Amortized Cost	793	4,417
Cash Equivalents [Member] | Treasuries and Government Agencies [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	'	1,000
Amortized Cost	'	1,000
Short-Term Marketable Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	26,633	40,617
Amortized Cost	26,581	40,602
Unrealized Gains	52	22
Unrealized Losses	'	-7
Short-Term Marketable Securities [Member] | Corporate Obligations and Commercial Paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	1,004	'
Amortized Cost	1,004	'
Short-Term Marketable Securities [Member] | State and Municipal Bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	10,552	33,250
Amortized Cost	10,551	33,251
Unrealized Gains	1	6
Unrealized Losses	'	-7
Short-Term Marketable Securities [Member] | Treasuries and Government Agencies [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	15,028	7,346
Amortized Cost	15,018	7,345
Unrealized Gains	10	1
Short-Term Marketable Securities [Member] | Equity Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	49	21
Amortized Cost	8	6
Unrealized Gains	41	15
Long-Term Marketable Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	8,804	20,071
Amortized Cost	8,802	20,073
Unrealized Gains	2	6
Unrealized Losses	'	-8
Long-Term Marketable Securities [Member] | Corporate Obligations and Commercial Paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	2,016	'
Amortized Cost	2,015	'
Unrealized Gains	1	'
Long-Term Marketable Securities [Member] | State and Municipal Bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	6,788	18,046
Amortized Cost	6,787	18,052
Unrealized Gains	1	2
Unrealized Losses	'	-8
Long-Term Marketable Securities [Member] | Treasuries and Government Agencies [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Market Value	'	2,025
Amortized Cost	'	2,021
Unrealized Gains	'	$4

Short_and_LongTerm_Marketable_4

Short and Long-Term Marketable Securities - Schedule of Available-for-Sale Debt Securities Mature (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'
Total	$36,181
Less Than One Year	27,377
One to Five Years	8,804
More than five years	'
State and Municipal Bonds [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Total	18,133
Less Than One Year	11,345
One to Five Years	6,788
More than five years	'
Treasuries and Government Agencies [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Total	15,028
Less Than One Year	15,028
One to Five Years	'
More than five years	'
Corporate Obligations and Commercial Paper [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Total	3,020
Less Than One Year	1,004
One to Five Years	2,016
More than five years	'

Acquisition_Additional_Informa

Acquisition - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Share data in Millions, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 24, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2014

Mar. 31, 2014

Palomar [Member]

Palomar [Member]

Palomar [Member]

Palomar [Member]

Palomar [Member]

Forecast [Member]

Forecast [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash consideration

'

'

'

'

'

'

'

'

'

'

'

$145,800,000

'

'

'

'

Number of shares issued

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

Cash and stock paid per merger agreement

'

'

'

'

'

'

'

'

'

'

'

287,204,000

'

'

'

'

Goodwill before acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

90,856,000

'

'

Goodwill after acquisition

95,183,000

'

'

'

15,811,000

'

'

'

95,183,000

15,811,000

'

79,345,000

79,345,000

'

'

'

Increase in intangible assets

'

'

'

'

'

'

'

'

'

'

'

'

12,020,000

'

'

'

Increased in accounts receivable

'

'

'

'

'

'

'

'

'

'

'

'

1,813,000

'

'

'

Decreased in inventory

'

'

'

'

'

'

'

'

'

'

'

'

1,609,000

'

'

'

Increased in fixed assets

'

'

'

'

'

'

'

'

'

'

'

'

530,000

'

'

'

Decrease in other assets

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

Accrued expenses increased

'

'

'

'

'

'

'

'

'

'

'

'

1,359,000

'

'

'

Deferred revenue increased

'

'

'

'

'

'

'

'

816,000

-135,000

2,395,000

'

518,000

'

'

'

Other long-term liabilities decreased

'

'

'

'

'

'

'

'

'

'

'

'

1,894,000

'

'

'

Cash and cash equivalents acquired

'

'

'

'

'

'

'

'

'

'

'

117,900,000

'

'

'

'

Revenue related to Palomar's operations

74,537,000

60,692,000

50,091,000

40,690,000

42,669,000

37,083,000

39,573,000

34,168,000

226,010,000

153,493,000

110,602,000

'

50,800,000

'

'

'

Control severance payments included in consolidated pro forma financial information

'

'

'

'

'

'

'

'

'

'

'

'

24,200,000

'

'

'

Amount associated with step up in fair value of finished goods inventory included in consolidated pro forma financial information

'

'

'

'

'

'

'

'

'

'

'

'

2,400,000

'

'

'

Acquisition related costs

'

'

'

'

'

'

'

'

'

'

'

'

32,400,000

'

'

'

Expense incurred due to change of control severance payments

'

'

'

'

'

'

'

'

'

'

'

'

24,200,000

'

'

'

Additional compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

500,000

Acquisition-related equity issuance costs

'

'

'

'

'

'

'

'

$568,000

'

'

'

$600,000

'

'

'

Acquisition_Estimated_Fair_Val

Acquisition - Estimated Fair Value of Net Assets Acquired (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Palomar [Member]	Palomar [Member]
Business Acquisition [Line Items]	'	'	'	'
Cash and stock paid	'	'	$287,204	'
Cash, cash equivalents and marketable securities acquired	'	'	-117,929	'
Purchase price, net	'	'	169,275	'
Assets (liabilities) acquired:	'	'	'	'
Accounts receivable	'	'	11,761	'
Inventory	'	'	20,054	'
Prepaids and other assets	'	'	722	'
Property and equipment	'	'	30,639	'
Other assets	'	'	132	'
Intangible assets	'	'	52,340	'
Goodwill	95,183	15,811	79,345	79,345
Accounts payable	'	'	-7,269	'
Accrued expenses	'	'	-9,771	'
Deferred revenue	'	'	-3,528	'
Deferred tax liability	'	'	-5,150	'
Total	'	'	$169,275	'

Acquisition_Proforma_Condensed

Acquisition - Pro-forma Condensed Consolidated Operating Results (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combinations [Abstract]	'	'
Revenue (unaudited)	$267,941	$231,153
Pre-tax income (loss) (unaudited)	$12,452	($42,199)

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Schedule of Changes to Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Balance-December 31, 2012	$15,811
Palomar acquisition	79,345
Translation adjustment	27
Balance-December 31, 2013	$95,183

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Schedule of Components of Other Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$61,995	$9,655
Translation adjustment	70	65
Accumulated amortization	-6,886	-3,783
Balance	55,179	5,937
Developed Technology and Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	27,510	3,250
Accumulated amortization	-2,216	-1,292
Balance	25,294	1,958
Business Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	384	384
Translation adjustment	40	38
Accumulated amortization	-239	-195
Balance	185	227
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	15,833	3,323
Translation adjustment	26	24
Accumulated amortization	-3,662	-2,019
Balance	12,197	1,328
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	16,930	2,650
Accumulated amortization	-761	-272
Balance	16,169	2,378
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	1,338	48
Translation adjustment	4	3
Accumulated amortization	-8	-5
Balance	$1,334	$46

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]	'	'	'
Period of amortized identifiable intangible assets	'12 years 3 months 18 days	'	'
Amortization expense	$3,100,000	$1,900,000	$1,200,000
Indefinite-life intangible assets	1,300,000	'	'
2014	8,375,000	'	'
2015	8,397,000	'	'
2016	7,616,000	'	'
2017	5,677,000	'	'
2018	4,222,000	'	'
2019 and Thereafter	19,561,000	'	'
Technology Patents [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Identifiable intangible assets acquired	24,200,000	'	'
Period of amortized identifiable intangible assets	'6 years 9 months 18 days	'	'
Customer Relationships [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Identifiable intangible assets acquired	12,500,000	'	'
Period of amortized identifiable intangible assets	'12 years 6 months	'	'
Trademarks [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Identifiable intangible assets acquired	14,300,000	'	'
Period of amortized identifiable intangible assets	'22 years 6 months	'	'
In Process Research and Development [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Identifiable intangible assets acquired	1,300,000	'	'
Cost of Revenues [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Amortization expense	500,000	'	'
Palomar [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Identifiable intangible assets acquired	52,300,000	'	'
Fair value of identifiable intangible assets acquired	52,300,000	'	'
Amortization expense	1,300,000	'	'
Palomar, Eleme Medical and ConBio Acquisitions [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
2014	2,900,000	'	'
2015	2,500,000	'	'
2016	2,100,000	'	'
2017	2,000,000	'	'
2018	1,900,000	'	'
2019 and Thereafter	$17,000,000	'	'

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Schedule of Amortization Expenses on Intangible Assets (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014	$8,375
2015	8,397
2016	7,616
2017	5,677
2018	4,222
2019 and Thereafter	19,561
Total	$53,848

Segment_and_Geographic_Informa2

Segment and Geographic Information - Schedule of Total Revenue by Geographic Destination (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	$74,537	$60,692	$50,091	$40,690	$42,669	$37,083	$39,573	$34,168	$226,010	$153,493	$110,602
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	111,179	72,704	43,903
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	39,529	28,808	27,918
Asia/Pacific [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	52,574	39,991	27,357
Other Country [Member]	'	'	'	'	'	'	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total revenue	'	'	'	'	'	'	'	'	$22,728	$11,990	$11,424

Segment_and_Geographic_Informa3

Segment and Geographic Information - Schedule of Total Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total assets	$414,494	$234,569
Operating Segments [Member] | United States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total assets	390,941	210,596
Operating Segments [Member] | Europe [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total assets	15,916	15,623
Operating Segments [Member] | Asia/Pacific [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total assets	11,496	11,038
Eliminations [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total assets	($3,859)	($2,688)

Segment_and_Geographic_Informa4

Segment and Geographic Information - Schedule of Long-Lived Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Long-lived assets	$28,123	$9,268
United States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Long-lived assets	24,120	7,266
Europe [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Long-lived assets	2,403	1,570
Asia/Pacific [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Long-lived assets	$1,600	$432

Segment_and_Geographic_Informa5

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2013
	Country
Segment Reporting [Abstract]	'
Number of individual countries with greater than 10% of total revenue, total assets or total long lived assets	0
Percentage of total revenue	10.00%

Balance_Sheet_Accounts_Propert

Balance Sheet Accounts - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$58,054	$35,820
Less: Accumulated depreciation and amortization	-31,609	-27,613
Property and Equipment, Net	26,445	8,207
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	7,835	5,098
Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'5 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	2,698	1,982
Furniture and Fixtures [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'5 years	'
Computer Equipment and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Property, Plant and Equipment, Gross	5,047	3,796
Leased Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	1,660	1,774
Leased Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Leased Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'4 years	'
Leased Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'14 years	'
Property, Plant and Equipment, Gross	13,327	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'5 years	'
Property, Plant and Equipment, Gross	2,898	2,504
Demonstration Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Property, Plant and Equipment, Gross	24,094	20,095
Construction in-Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$495	$571

Balance_Sheet_Accounts_Additio

Balance Sheet Accounts - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Balance Sheet Related Disclosures [Abstract]	'	'	'
Depreciation expenses	$6,000,000	$5,000,000	$5,700,000
Cost of assets recorded under capitalized leases	15,000,000	1,800,000	'
Related accumulated amortization	1,200,000	900,000	'
Long-lived assets held for sale	25,100,000	'	'
Impairment loss incurred	$607,000	'	'

Balance_Sheet_Accounts_Accrued

Balance Sheet Accounts - Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Accrued payroll and taxes	$9,547	$3,039
Accrued employee benefits	2,093	1,149
Accrued warranty costs	6,651	3,415
Accrued commissions	5,243	2,620
Accrued other	13,443	6,978
Accrued Expenses, Total	$36,977	$17,201

Balance_Sheet_Accounts_Other_N

Balance Sheet Accounts - Other Noncurrent Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Noncurrent deferred rent	$2	$1,473
Noncurrent deferred tax liability	8,512	473
Noncurrent income tax reserve	51	319
Total other noncurrent liabilities	$8,565	$2,265

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Party Transaction [Line Items]	'	'	'
Percentage of common stock outstanding	10.00%	'	'
Purchases of inventory from related party	$4,700,000	$5,800,000	$7,800,000
Due to related party for purchase of inventory	1,300,000	1,900,000	'
Amounts due from related party	$0	$0	'
El.En. S.p.A [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Shares of common stock owned by related party	2,098,628	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 29, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
In Millions, except Share data, unless otherwise specified				Common Stock Class A [Member]	Common Stock Class A [Member]	Common Stock Class A [Member]	Common Stock Class A [Member]	Common Stock Class B [Member]	Common Stock Class B [Member]
							Secondary Public Offering [Member]
Schedule Of Equity [Line Items]	'	'	'	'	'	'	'	'	'
Common stock, par value	$0.00	'	'	'	$0.00	$0.00	'	$0.00	$0.00
Class A and Class B common stock, shares authorized	70,000,000	70,000,000	'	'	61,500,000	'	'	8,500,000	'
Public offering of common stock, shares	'	'	'	'	'	'	2,840,000	'	'
Secondary public offering of common stock, shares	'	'	'	'	'	840,000	'	'	'
Common stock, shares issued	'	'	'	'	22,632,749	16,402,000	'	0	0
Common Stock, shares outstanding	'	'	'	'	'	'	'	0	0
Common stock conversion ratio	'	'	1	'	'	'	'	'	1
Preferred stock, par value	$0.00	$0.00	'	'	'	'	'	'	'
Preferred stock, shares authorized	5,000,000	5,000,000	'	'	'	'	'	'	'
Number of shares authorized to be repurchased	'	'	'	$25	'	'	'	'	'
Treasury stock repurchased	'	'	'	'	653,301	'	'	'	'
Weighted average per share price of treasury stock	'	'	'	'	$23.54	'	'	'	'
Treasury stock acquired aggregate cost	'	'	'	'	15.4	'	'	'	'
Aggregate treasury stock repurchased	'	'	'	'	886,407	'	'	'	'
Treasury stock acquired aggregate cost	'	'	'	'	$17.60	'	'	'	'
Stock repurchase authorization description	'	'	'	'	'On October 29, 2013, Cynosure announced that its board of directors authorized the repurchase of up to $25 million of its Class A common stock, from time to time, on the open market or in privately negotiated transactions under a stock repurchase program. The program will terminate upon the purchase of $25 million in common stock or expiration of the program on November 1, 2015	'	'	'	'
Expiration date of program	'	'	'	'	1-Nov-15	'	'	'	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Apr. 30, 2013

Dec. 31, 2013

2004 Stock Option Plan [Member]

2004 Stock Option Plan [Member]

2004 Stock Option Plan [Member]

2004 Stock Option Plan [Member]

2004 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

2005 Stock Option Plan [Member]

Common Stock Class A [Member]

Common Stock Class A [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation fair market value percentage

'

'

'

'

110.00%

'

'

'

'

110.00%

'

'

Stock based compensation voting stock percentage

'

'

'

'

10.00%

'

'

'

'

10.00%

'

'

Stock option exceed in year

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'

Option granted period

'

'

'

'

'48 months

'

'

'

'

'36 months

'

'

Stock option plan vested in percentage

6.25%

6.25%

6.25%

6.25%

25.00%

8.33%

8.33%

8.33%

8.33%

'

'

'

Shares available for future grant

0

'

'

'

0

2,277,659

'

'

'

2,277,659

'

'

Common stock shares reserved for future issuance under stock based plan

'

'

'

'

'

'

'

'

'

'

'

5,588,369

Common stock shares reserved for future increase in shares

'

'

'

'

'

'

'

'

'

'

2,500,000

'

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Granted, Number of Options	617,510	'
Exercise, Number of Options	-202,603	'
Forfeited, Number of Options	-63,652	'
Outstanding, Number of Options, Beginning Balance	'	1,952,611
Outstanding, Weighted-Average Exercise Price, Beginning balance	'	$16.18
Outstanding, Aggregate Intrinsic Value, Beginning balance	'	$16,114
Outstanding, Number of Options, Ending balance	2,303,866	'
Vested, Number of Options	1,596,565	1,424,788
Unvested, Number of Options	707,301	527,823
Vested or expected to vest, Number of Options	2,285,851	'
Exercisable, Number of Options	1,596,565	'
Granted, Exercise Price Range, Lower Limit	$22.12	'
Exercise, Exercise Price Range, Lower Limit	$3	'
Forfeited, Exercise Price Range, Lower Limit	$6.78	'
Outstanding, Exercise Price Range, Lower Limit Beginning Balance	$3	$3
Vested, Exercise Price Range, Lower Limit	$3	$3
Unvested, Exercise Price Range, Lower Limit	$9.56	$9.56
Vested or expected to vest, Exercise Price Range, Lower Limit	$3	'
Exercisable, Exercise Price Range, Lower Limit	$3	'
Granted, Exercise Price Range, Upper Limit	$28.68	'
Exercised, Exercise Price Range, Upper Limit	$21.73	'
Forfeited, Exercise Price Range, Upper Limit	$36.94	'
Outstanding, Exercise Price Range, Upper Limit Beginning Balance	$36.94	$36.94
Vested, Exercise Price Range, Upper Limit	$36.94	$36.94
Unvested, Exercise Price Range, Upper Limit	$28.68	$24.99
Vested or expected to vest, Exercise Price Range, Upper Limit	$36.94	'
Exercisable, Exercise Price Range, Upper Limit	$36.94	'
Granted, Weighted-Average Exercise Price	$25.73	'
Exercise, Weighted-Average Exercise Price	$13.43	'
Forfeited, Weighted-Average Exercise Price	$22.63	'
Outstanding, Weighted-Average Exercise Price, Ending balance	$18.81	'
Vested, Weighted-Average Exercise Price	$16.93	$16.20
Unvested, Weighted-Average Exercise Price	$23.06	$16.15
Vested or expected to vest, Weighted-Average Exercise Price	$18.75	'
Exercisable, Weighted average exercise price	$16.93	'
Outstanding Weighted-Average Remaining Contractual Life, Beginning balance	'6 years 6 months 4 days	'6 years 5 months 27 days
Vested, Weighted-Average Remaining Contractual Life	'5 years 4 months 6 days	'
Unvested, Weighted-Average Remaining Contractual Life	'9 years 1 month 17 days	'
Vested or expected to vest, Weighted-Average Remaining Contractual Life	'6 years 5 months 27 days	'
Exercisable, Weighted-Average Remaining Contractual Life	'5 years 4 months 6 days	'
Granted, Aggregate Intrinsic Value	1,184	'
Exercise, Aggregate Intrinsic Value	2,345	'
Forfeited, Aggregate Intrinsic Value	293	'
Outstanding, Aggregate Intrinsic Value, Ending balance	19,046	'
Vested, Aggregate Intrinsic Value	16,061	11,890
Unvested, Aggregate Intrinsic value	2,985	4,224
Vested or expected to vest, Aggregate Intrinsic value	19,008	'
Exercisable, Aggregate Intrinsic Value	$16,061	'

Income_Taxes_Loss_Income_befor

Income Taxes - (Loss) Income before Income Tax (Benefit) Provision (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Domestic	($8,633)	$10,344	($2,710)
Foreign	3,096	2,381	612
(Loss) income before (benefit) provision for income taxes	($5,537)	$12,725	($2,098)

Income_Taxes_Benefit_Provision

Income Taxes - (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$732	$1,382	$241
State	214	128	179
Foreign	890	606	433
Total current	1,836	2,116	853
Deferred:	'	'	'
Federal	-5,406	152	'
State	-304	'	'
Foreign	-16	-504	-46
Total deferred	-5,726	-352	-46
Income tax expense (benefits)	($3,890)	$1,764	$807

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Income tax provision at federal statutory rate:	35.00%	35.00%	35.00%
Increase (decrease) in tax resulting from -	'	'	'
State taxes, net of federal benefit	-3.10%	0.70%	-8.90%
Nondeductible expenses	-11.90%	2.10%	-12.10%
Tax-exempt interest income	0.50%	-0.30%	1.40%
Effect of foreign taxes	2.70%	-1.80%	3.60%
Stock-based compensation	-0.10%	-0.90%	-0.60%
Research and development credit	25.80%	'	23.90%
Change in uncertain tax positions	4.80%	2.50%	'
Change in valuation allowance	162.00%	-20.50%	-81.50%
Change in control payments	-128.80%	'	'
Transaction costs	-13.60%	'	'
Other	-3.10%	-2.90%	0.70%
Effective income tax rate	70.20%	13.90%	-38.50%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Accrued expenses and reserves	$9,747	$2,741
Domestic net operating loss & tax credit carry-forwards	19,925	1,692
Foreign net operating loss carry-forwards	2,022	682
Stock-based compensation	6,020	5,620
Capital leases	5,472	'
Intangible assets	'	520
Other deferred tax assets	1,636	1,854
Gross deferred tax assets	44,822	13,109
Valuation allowance	-19,186	-11,804
Total deferred tax assets (after valuation allowance)	25,636	1,305
Intangible assets	-18,227	'
Fixed assets	-5,463	-387
Other deferred tax liabilities	-534	'
Total long-term deferred tax liabilities	-24,224	-387
Net deferred tax assets	$1,412	$918

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
(Benefit) provision for income taxes	($3,890,000)	$1,764,000	$807,000	'
Effective tax rate	70.20%	13.90%	-38.50%	'
Provision for income tax	1,700,000	'	'	'
Additional deferred tax liabilities to be set off against future income	41,200,000	'	'	'
Domestic federal net operating loss carry-forwards	4,700,000	'	'	'
State tax credit carry-forwards	1,700,000	'	'	'
State net operating loss carry-forwards	2,300,000	'	'	'
Federal tax credit carry-forwards related to excess stock based compensation	1,100,000	'	'	'
State tax credit carry-forwards related to excess stock based compensation	100,000	'	'	'
Federal net operating losses, expiration start year	'2020	'	'	'
State net operating losses, expiration start year	'2014	'	'	'
Federal and State tax credits, expiration start year	'2018	'	'	'
Foreign net operating loss carry-forwards	2,022,000	682,000	'	'
Undistributed earnings of foreign subsidiaries	13,600,000	'	'	'
Unrecognized tax benefits	1,701,000	586,000	'	'
Unrecognized tax benefit if recognized would impact effective tax rate	100,000	300,000	'	'
Japan [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Net operating loss carry-forward expiry period	'2019	'	'	'
Mexican [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Net operating loss carry-forward expiry period	'2019	'	'	'
Spain [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Net operating loss carry-forward expiry period	'2029	'	'	'
Palomar [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Unrecognized tax benefit resulting from acquisition	5,600,000	'	'	'
Increase in income tax valuation allowance	7,400,000	'	'	'
United States [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Domestic federal net operating loss carry-forwards	400,000	'	'	'
Federal tax credit carry-forwards	7,300,000	'	'	'
Foreign Tax Authority [Member]	'	'	'	'
Deferred Tax Assets And Liabilities Classification [Line Items]	'	'	'	'
Foreign net operating loss carry-forwards	$6,100,000	'	'	'

Income_Taxes_Changes_in_Gross_

Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns [Roll Forward]	'	'	'
Balance at beginning of year	$586	'	'
Increases for tax positions taken during current period	76	398	'
Increases for tax positions taken in prior periods	'	188	'
Increases for acquired tax positions taken in prior periods	1,625	'	'
Decreases for tax positions taken in prior periods	-398	'	'
Decreases for lapse in statutes	-188	'	'
Balance at end of year	$1,701	$586	'

401k_Plans_Additional_Informat

401(k) Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Sale Of Subsidiary [Abstract]	'	'	'
Total contributions to this plan	$579,000	$419,000	$357,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Lease
Operating Leased Assets [Line Items]	'	'	'
Operating lease expiration period	'2027-05	'	'
Lease extension period	'5 years	'	'
Rent under the lease abated period	'21 months	'	'
Number of lease extension options	2	'	'
Operating lease rent expense	$2.40	$2.10	$1.80
Five Carlisle Road [Member]	'	'	'
Operating Leased Assets [Line Items]	'	'	'
Percentage of capital leases	10.80%	'	'
Three Carlisle Road [Member]	'	'	'
Operating Leased Assets [Line Items]	'	'	'
Percentage of capital leases	8.80%	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Operating Facility, Certain Equipment and Vehicles Under Operating Lease and Capital Lease Agreements with Payments (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'	'
2014	$1,330	'
2015	776	'
2016	889	'
2017	903	'
2018	847	'
Thereafter	2,910	'
Total minimum lease payments	7,655	'
2014	701	'
2015	115	'
2016	2,069	'
2017	2,524	'
2018	2,516	'
Thereafter	22,677	'
Total minimum lease payments	30,602	'
Less amount representing interest	-15,359	'
Present value of obligations under capital leases	15,243	'
Current portion of capital lease obligations	286	322
Capital lease obligations, net of current portion	$14,957	$432

Summary_Selected_Quarterly_Fin2

Summary Selected Quarterly Financial Data (Unaudited) - Unaudited Consolidated Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$74,537	$60,692	$50,091	$40,690	$42,669	$37,083	$39,573	$34,168	$226,010	$153,493	$110,602
Gross profit	44,672	34,134	27,787	23,687	24,791	21,587	23,040	19,508	130,280	88,926	62,308
Income (loss) from operations	8,250	-1,426	-14,639	1,988	4,239	3,343	3,693	858	-5,827	12,133	-2,022
Net income (loss)	$7,349	($1,281)	($8,954)	$1,239	$4,039	$3,423	$2,680	$819	($1,647)	$10,961	($2,905)
Basic net income (loss) per share	$0.33	($0.06)	($0.54)	$0.08	$0.28	$0.26	$0.21	$0.07	($0.09)	$0.83	($0.23)
Diluted net income (loss) per share	$0.33	($0.06)	($0.54)	$0.07	$0.27	$0.25	$0.20	$0.06	($0.09)	$0.79	($0.23)